

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

EPAS ID: PAT7483300

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
SEQUENCE:	1

CONVEYING PARTY DATA

Name	Execution Date
THE SCRIPPS RESEARCH INSTITUTE	04/01/2022

RECEIVING PARTY DATA

Name:	UNIVERSITY OF FLORIDA BOARD OF TRUSTEES
Street Address:	111 TIGERT HALL
Internal Address:	P.O. BOX 113157
City:	GAINESVILLE
State/Country:	FLORIDA
Postal Code:	32611

PROPERTY NUMBERS Total: 11

Property Type	Number
Application Number:	17602924
Application Number:	15545117
Application Number:	15545152
Application Number:	16423362
Application Number:	15545168
Application Number:	16439950
Application Number:	16949983
Application Number:	16085100
Application Number:	14779191
Application Number:	17768896
Application Number:	63291771

CORRESPONDENCE DATA

Fax Number: (617)646-8646

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Phone: 6176468000

Email: stacey.appleton@wolfgreenfield.com

Correspondent Name: WOLF GREENFIELD & SACKS, P.C.

Address Line 1: 600 ATLANTIC AVENUE

PATENT

Address Line 4: BOSTON, MASSACHUSETTS 02210

ATTORNEY DOCKET NUMBER: U1196.70096US01

NAME OF SUBMITTER: STACEY L. APPLETON

SIGNATURE: /STACEY L. APPLETON/

DATE SIGNED: 08/12/2022

Total Attachments: 55

source=U119670096US01-ASI-DMF(TSRI to UFL)#page1.tif
source=U119670096US01-ASI-DMF(TSRI to UFL)#page2.tif
source=U119670096US01-ASI-DMF(TSRI to UFL)#page3.tif
source=U119670096US01-ASI-DMF(TSRI to UFL)#page4.tif
source=U119670096US01-ASI-DMF(TSRI to UFL)#page5.tif
source=U119670096US01-ASI-DMF(TSRI to UFL)#page6.tif
source=U119670096US01-ASI-DMF(TSRI to UFL)#page7.tif
source=U119670096US01-ASI-DMF(TSRI to UFL)#page8.tif
source=U119670096US01-ASI-DMF(TSRI to UFL)#page9.tif
source=U119670096US01-ASI-DMF(TSRI to UFL)#page10.tif
source=U119670096US01-ASI-DMF(TSRI to UFL)#page11.tif
source=U119670096US01-ASI-DMF(TSRI to UFL)#page12.tif
source=U119670096US01-ASI-DMF(TSRI to UFL)#page13.tif
source=U119670096US01-ASI-DMF(TSRI to UFL)#page14.tif
source=U119670096US01-ASI-DMF(TSRI to UFL)#page15.tif
source=U119670096US01-ASI-DMF(TSRI to UFL)#page16.tif
source=U119670096US01-ASI-DMF(TSRI to UFL)#page17.tif
source=U119670096US01-ASI-DMF(TSRI to UFL)#page18.tif
source=U119670096US01-ASI-DMF(TSRI to UFL)#page19.tif
source=U119670096US01-ASI-DMF(TSRI to UFL)#page20.tif
source=U119670096US01-ASI-DMF(TSRI to UFL)#page21.tif
source=U119670096US01-ASI-DMF(TSRI to UFL)#page22.tif
source=U119670096US01-ASI-DMF(TSRI to UFL)#page23.tif
source=U119670096US01-ASI-DMF(TSRI to UFL)#page24.tif
source=U119670096US01-ASI-DMF(TSRI to UFL)#page25.tif
source=U119670096US01-ASI-DMF(TSRI to UFL)#page26.tif
source=U119670096US01-ASI-DMF(TSRI to UFL)#page27.tif
source=U119670096US01-ASI-DMF(TSRI to UFL)#page28.tif
source=U119670096US01-ASI-DMF(TSRI to UFL)#page29.tif
source=U119670096US01-ASI-DMF(TSRI to UFL)#page30.tif
source=U119670096US01-ASI-DMF(TSRI to UFL)#page31.tif
source=U119670096US01-ASI-DMF(TSRI to UFL)#page32.tif
source=U119670096US01-ASI-DMF(TSRI to UFL)#page33.tif
source=U119670096US01-ASI-DMF(TSRI to UFL)#page34.tif
source=U119670096US01-ASI-DMF(TSRI to UFL)#page35.tif
source=U119670096US01-ASI-DMF(TSRI to UFL)#page36.tif
source=U119670096US01-ASI-DMF(TSRI to UFL)#page37.tif
source=U119670096US01-ASI-DMF(TSRI to UFL)#page38.tif
source=U119670096US01-ASI-DMF(TSRI to UFL)#page39.tif
source=U119670096US01-ASI-DMF(TSRI to UFL)#page40.tif

source=U119670096US01-ASI-DMF(TSRI to UFL)#page41.tif
source=U119670096US01-ASI-DMF(TSRI to UFL)#page42.tif
source=U119670096US01-ASI-DMF(TSRI to UFL)#page43.tif
source=U119670096US01-ASI-DMF(TSRI to UFL)#page44.tif
source=U119670096US01-ASI-DMF(TSRI to UFL)#page45.tif
source=U119670096US01-ASI-DMF(TSRI to UFL)#page46.tif
source=U119670096US01-ASI-DMF(TSRI to UFL)#page47.tif
source=U119670096US01-ASI-DMF(TSRI to UFL)#page48.tif
source=U119670096US01-ASI-DMF(TSRI to UFL)#page49.tif
source=U119670096US01-ASI-DMF(TSRI to UFL)#page50.tif
source=U119670096US01-ASI-DMF(TSRI to UFL)#page51.tif
source=U119670096US01-ASI-DMF(TSRI to UFL)#page52.tif
source=U119670096US01-ASI-DMF(TSRI to UFL)#page53.tif
source=U119670096US01-ASI-DMF(TSRI to UFL)#page54.tif
source=U119670096US01-ASI-DMF(TSRI to UFL)#page55.tif

ASSIGNMENT AND ASSUMPTION AGREEMENT OF TRANSFERRED IP ASSETS

This ASSIGNMENT AND ASSUMPTION AGREEMENT OF TRANSFERRED IP ASSETS (this “**Agreement**”) is made and entered into as of April 1, 2022 (the “**Effective Date**”), by and between The Scripps Research Institute, a California nonprofit public benefit corporation and registered to do business in Florida (“**Assignor**”) and University of Florida Board of Trustees, a Florida not for profit corporation (“**Assignee**”). Assignor and Assignee are referred to herein, individually, as a “**Party**” or, collectively, as the “**Parties**.”

WITNESSETH:

WHEREAS, Assignor and Assignee are parties to that certain Asset Transfer Agreement dated November 15, 2021, as amended by that certain Amendment No. 1 to the Asset Transfer Agreement, dated December 22, 2021 (together, the “**Asset Transfer Agreement**”), pursuant to which, among other things, Assignor has agreed to assign to Assignee, and Assignee has agreed to accept from Assignor, as of the Closing, all of Assignor’s right, title and interest in and to all Transferred IP Assets,

WHEREAS, to provide a document for recording, as applicable, with the United States Patent and Trademark Office, the United States Copyright Office, and the corresponding entities or agencies in any applicable jurisdictions, Assignor and Assignee are executing this Agreement.

NOW, THEREFORE, in consideration of the foregoing and of the mutual covenants and agreements set forth herein, and for other good and valuable consideration, the receipt and adequacy of which is hereby acknowledged, the Parties agree as follows:

1. **Definitions.** All capitalized terms used, but not defined herein, shall have the meanings ascribed to such terms in the Asset Transfer Agreement.

2. **Recitals.** The recitals set forth above are, by this reference, incorporated into and deemed part of this Agreement.

3. **Assignment.** For good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Assignor hereby irrevocably sells, transfers, assigns, and delivers to Assignee all of Assignor’s respective right, title and interest in and to all Transferred IP Assets, including without limitation (i) the Intellectual Property within the Transferred IP Assets set forth in Schedule 1 hereof, (ii) all common law rights and goodwill associated therewith, and the entire right, title and interest in and to any and all royalties, fees, income, payments, and other proceeds now or hereafter due or payable to TSRI with respect to such Intellectual Property, as well as Actions and causes of action in favor of TSRI with respect to such Intellectual Property, whether accruing before, on, or after the date hereof/accruing on or after the date hereof, including all rights to and Actions for damages, restitution, and injunctive and other legal or equitable relief for past, present, or future infringement, misappropriation, or other violation thereof, to have and to hold such Intellectual Property forever, (iii) the right to secure registration of such Intellectual Property and of this Agreement, (iv) the right to initiate other proceedings before all government and administrative bodies with respect to such Intellectual Property, and the right to claim priority, file foreign counterparts and make applications for reissue and reexamination with respect to any of such Intellectual Property.

4. **Acceptance.** Assignee hereby accepts the foregoing assignment of all Transferred IP Assets, pursuant to this Agreement, and assumes all right, title and interest of Assignor with respect to the Transferred IP Assets.

5. **Recordation and other actions.** Assignor hereby authorizes the Commissioner for Patents in the United States Patent and Trademark Office, the Register of Copyrights in the United States Copyright Office, and the officials of corresponding entities or agencies in any applicable jurisdictions, to record and

register this Agreement and to record the Assignee as the owner of the Transferred IP Assets and all Intellectual Property therein upon request by Assignee. Following the date hereof, upon Assignee's reasonable request, Assignor shall at Assignee's expense take such steps and actions, and provide such cooperation and assistance to Assignee and its successors, assigns, and legal representatives, including the execution and delivery of any affidavits, declarations, oaths, exhibits, assignments, powers of attorney, or other documents, as may be reasonably necessary to effect or perfect the assignment of the Transferred IP Assets to Assignee, or any other assignee or successor thereto.

6. Terms of the Asset Transfer Agreement. The Parties acknowledge and agree that this Agreement is entered into pursuant to the Asset Transfer Agreement, to which reference is made for a further statement of the rights and obligations of the Assignee and Assignor with respect to the Transferred IP Assets. Notwithstanding anything to the contrary contained in this Agreement, nothing contained herein is intended to or shall be deemed to limit, restrict, modify, alter, amend or otherwise change in any manner the rights and obligations of Assignor or Assignee under the Asset Transfer Agreement. Nothing herein shall be deemed to enlarge, modify or alter in any way the representations and warranties or the rights and remedies of the Parties under the Asset Transfer Agreement. The representations, warranties, covenants, agreements, and indemnities contained in the Asset Transfer Agreement and the Conveyance will not be superseded hereby but shall remain in full force and effect to the full extent provided therein. In the event of a conflict or inconsistency between the terms of the Asset Transfer Agreement and the terms of this Agreement, the terms of the Asset Transfer Agreement will govern.

7. Counterparts. This Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same agreement.

8. Further Assurances. Assignor and Assignee each agree to do such further acts and things and to execute and deliver such additional agreements and instruments as may reasonably be required to consummate, evidence or confirm the assignments and agreements contained herein. Without limiting the foregoing, Assignor shall upon Assignee's request transfer to Assignee or its designee the files and records of Assignor concerning the prosecution of all Intellectual Property within the Transferred IP Assets.

9. Section Headings. The descriptive headings herein are inserted for convenience only and are not intended to be part of or to affect the meaning or interpretation of this Agreement.

10. Governing Law. This Agreement shall be governed by and construed in accordance with the laws of the State of Florida (without giving effect to conflict of law principles) as to all matters, including but not limited to matters of validity, construction, effect, performance and remedies.

11. Successors. This Agreement shall be binding upon and inure to the benefit of the Parties hereto and their successors and assigns.

12. Severability. In the event that any provision of this Agreement shall be unenforceable or inoperative as a matter of law, the remaining provisions shall remain in full force and effect.

13. Authority. Each Party represents and warrants to the other that it is fully authorized to execute and deliver this Agreement, and that the individual signing this Agreement on behalf of such Party is fully authorized to do so.

[Signature Page Follows]

IN WITNESS WHEREOF, the Parties have caused this Assignment and Assumption Agreement of Transferred IP Assets to be executed as of the date first above written.

ASSIGNOR:

THE SCRIPPS RESEARCH INSTITUTE

By: DocuSigned by: Matt Tremblay

Name: Matt Tremblay

Title: COO

ASSIGNEE:

UNIVERSITY OF FLORIDA BOARD OF TRUSTEES

By: _____

Name: David Nelson

Title: President, UF Health

IN WITNESS WHEREOF, the Parties have caused this Assignment and Assumption Agreement of Transferred IP Assets to be executed as of the date first above written.

ASSIGNOR:

THE SCRIPPS RESEARCH INSTITUTE


By: _____

Name: Matt Tremblay

Title: COO

ASSIGNEE:

UNIVERSITY OF FLORIDA BOARD OF TRUSTEES

By:  _____
C2B896DD6B0242A...

Name: David Nelson

Title: President, UF Health

Schedule 1

Intellectual Property

Trademarks

Serial Number	Registration Number	Title	Filing Date	Last Issue Date
US 76/556,570	US 4,150,314	“SCRIPPS FLORIDA” AND DESIGN (INT’L CLASS 16, 41, 42)	11/4/03	5/29/21
US 76/555,587	US 4,150,313	“SCRIPPS FLORIDA” (CLASS 16, 41, 42)	10/31/03	5/29/21

Patents

TSRI Reference Number	Serial Number	Patent Number	Inventors	Title
CUR 0001P	60/754,463		WAHLESTEDT	NATURAL ANTISENSE AND NON-CODING RNA TRANSCRIPTS AS DRUG TARGETS (DISCL. NO. 05-190; MS 17944-PH) (PROVISIONAL)
CUR 0007P	200680053539.7		WAHLSTEDT	NATURAL ANTISENSE AND NON-CODING RNA TRANSCRIPTS AS DRUG TARGETS (CHINA)
CUR 0009P	201310106246.2		WAHLSTEDT	NATURAL ANTISENSE AND NON-CODING RNA TRANSCRIPTS AS DRUG TARGETS (CHINA/DIV 1)
CUR 0008P	13/563,581	9,803,195	WAHLSTEDT	NATURAL ANTISENSE AND NON-CODING RNA TRANSCRIPTS AS DRUG TARGETS (DISCL. NO. 05-190; MS 17944) (CON 1)
CUR 0010P	15/257,696		WAHLSTEDT	NATURAL ANTISENSE AND NON-CODING RNA TRANSCRIPTS AS DRUG TARGETS (DISCL. NO. 05-190) (CON 2)
CUR 0011P	15/716,093	10,472,627	WAHLSTEDT	NATURAL ANTISENSE AND NON-CODING RNA TRANSCRIPTS AS DRUG TARGETS (DISCL. NO. 05-190; MS 17944) (DIV 1)
CUR 0003P	06850393.7		WAHLSTEDT	NATURAL ANTISENSE AND NON-CODING RNA TRANSCRIPTS AS DRUG TARGETS (EPO)

4824-8276-4537.3

CUR 0004P	6682/2008		WAHLSTEDT	NATURAL ANTISENSE AND NON-CODING RNA TRANSCRIPTS AS DRUG TARGETS (INDIA)
CUR 0005P	2008-548851		WAHLSTEDT	NATURAL ANTISENSE AND NON-CODING RNA TRANSCRIPTS AS DRUG TARGETS (JAPAN)
CUR 0002P	06/062672	WO 07/087113	WAHLESTEDT	NATURAL ANTISENSE AND NON-CODING RNA TRANSCRIPTS AS DRUG TARGETS (DISCL. NO. 05-190) (PCT)
CUR 0006P	12/159,607	8,288,354	WAHLSTEDT	NATURAL ANTISENSE AND NON-CODING RNA TRANSCRIPTS AS DRUG TARGETS (DISCL. NO. 05-190; MS 17944) (U.S. NATIONAL PHASE)
FLA 0061P	61/349,336		AYAD, ROUSH, RAHAIM, SIMANSKI	WEE1 DEGRADATION INHIBITORS (DISCL. NO. 09-73, 10-08; MS 20757) (PROVISIONAL)
FLA 0090P	61/604,683		ROUSH, AYAD, RAHAIM, SIMANSKI	WEE1 DEGRADATION INHIBITORS (DISCL. NO. 09-73, 10-08; MS 20757) (PROVISIONAL)
FLA 0146P			AYAD, ROUSH, RAHAIM, SIMANSKI, BIBIAN	WEE1 DEGRADATION INHIBITORS (AUSTRALIA)
FLA 0147P			AYAD, ROUSH, RAHAIM, SIMANSKI, BIBIAN	WEE1 DEGRADATION INHIBITORS (EPO)
FLA 0148P			AYAD, ROUSH, RAHAIM, SIMANSKI, BIBIAN	WEE1 DEGRADATION INHIBITORS (JAPAN)
FLA 0104P	13/027784	WO 13/130461	AYAD, ROUSH, RAHAIM, SIMANSKI, BIBIAN	WEE1 DEGRADATION INHIBITORS (PCT)
FLA 0149P	14/381,151	9,493,464	ROUSH, RAHAIM, BIBIAN	WEE1 DEGRADATION INHIBITORS (DISCL. NO. 09-73, 10-08; MS 20757) (U.S. NATIONAL PHASE) [CPA-N]
TSR 1371P	61/316,465		ZACK, BANNISTER, ROUSH, VOJKOVSKY, YANG, BERLINICKE	NOVEL INHIBITORS OF PROTEIN KINASE SIGNALING THAT ARE NEUROPROTECTIVE AND HAVE POTENTIAL APPLICABILITY FOR THE

TSR 2382P	14/886,938	9,539,239	ZACK, BANNISTER, VOJKOVSKY, YANG, BERLINICKE	TREATMENT OF GLAUCOMA, OPTIC NERVE DISEASE, AND OTHER FORMS OF NEURODEGENERATION (DISC. NO. 09-195) (PROVISIONAL) COMPOSITIONS AND METHODS FOR TREATMENT OF NEURODEGENERATIVE DISEASE (CON 1) NOVEL INHIBITORS OF PROTEIN KINASE SIGNALING THAT ARE NEUROPROTECTIVE AND HAVE POTENTIAL APPLICABILITY FOR THE TREATMENT OF
TSR 1714P	11760179.9		ZACK, BANNISTER, ROUSH, VOJKOVSKY, YANG, BERLINICKE	GLAUCOMA, OPTIC NERVE DISEASE, AND OTHER FORMS OF NEURODEGENERATION (EPO)
TSR 1713P	11/029689	WO 11/119777	ZACK, BANNISTER, ROUSH, VOJKOVSKY, YANG, BERLINICKE	COMPOSITIONS AND METHODS FOR TREATMENT OF NEURODEGENERATIVE DISEASE (PCT)
TSR 1715P	13/636,415	9,162,981	ZACK, BANNISTER, VOJKOVSKY, YANG, BERLINICKE	COMPOSITIONS AND METHODS FOR TREATMENT OF NEURODEGENERATIVE DISEASE (U.S. NATIONAL PHASE) HIGH-THROUGHPUT SCREENING FOR COMPOUNDS MODULATING LEVELS OF CELLULAR MACROMOLECULES
FLA 0079P	61/472,962		WEISSMANN, LASMEZAS	(DISCL. NO. 10-136) (PROVISIONAL) HIGH-THROUGHPUT SCREENING FOR COMPOUNDS MODULATING EXPRESSION OF CELLULAR MACROMOLECULES
FLA 0173P	2012239943	2012239943	WEISSMANN, LASMEZAS	(AUSTRALIA) HIGH-THROUGHPUT SCREENING FOR COMPOUNDS
FLA 0174P	2,832,480		WEISSMANN, LASMEZAS	SCREENING FOR COMPOUNDS

FLA 0270P	15/438,949		WEISSMANN, LASMEZAS	MODULATING EXPRESSION OF CELLULAR MACROMOLECULES (CANADA) HIGH-THROUGHPUT SCREENING FOR COMPOUNDS MODULATING EXPRESSION OF CELLULAR MACROMOLECULES (DIV 1) HIGH-THROUGHPUT SCREENING FOR COMPOUNDS MODULATING EXPRESSION OF CELLULAR MACROMOLECULES (EPO)
FLA 0175P	12768275.5	2694964	WEISSMANN, LASMEZAS	HIGH-THROUGHPUT SCREENING FOR COMPOUNDS MODULATING EXPRESSION OF CELLULAR MACROMOLECULES (HONG KONG)
FLA 0176P	14108234.3		WEISSMANN, LASMEZAS	HIGH-THROUGHPUT SCREENING FOR COMPOUNDS MODULATING EXPRESSION OF CELLULAR MACROMOLECULES (JAPAN)
FLA 0177P	2014-504041		WEISSMANN, LASMEZAS	HIGH-THROUGHPUT SCREENING FOR COMPOUNDS MODULATING EXPRESSION OF CELLULAR MACROMOLECULES (PCT)
FLA 0091P	12/032587	WO 12/139040	WEISSMANN, LASMEZAS	HIGH-THROUGHPUT SCREENING FOR COMPOUNDS MODULATING EXPRESSION OF CELLULAR MACROMOLECULES (RUSSIAN FEDERATION)
FLA 0178P	2013144610	2612017	WEISSMANN, LASMEZAS	HIGH-THROUGHPUT SCREENING FOR COMPOUNDS MODULATING
FLA 0179P	14/046,483	9,612,238	WEISSMANN, LASMEZAS	

				EXPRESSION OF CELLULAR MACROMOLECULES (U.S. NATIONAL PHASE)
ADI 0002P	61/493,883		KAMENECKA, GRIFFIN	N- BIPHENYLMETHYLINDOL E MODULATORS OF PPARG (DISCL. NO. 11-05) (PROVISIONAL)
ADI 0010P	61/554,605		KAMENECKA, GRIFFIN KAMENECKA, GRIFFIN,	N- BIPHENYLMETHYLINDOL E MODULATORS OF PPARG (DISCL. NO. 11-05) (PROVISIONAL)
ADI 0016P	13/490,324	8,957,093	KOENIG, ASTEIAN, BLAYO, HE, SHIN KAMENECKA, GRIFFIN,	N- BIPHENYLMETHYLINDOL E MODULATORS OF PPARG (DISCL. NO. 11-05) [CPA-N]
ADI 0017P	12/041129	WO 12/170554	KOENIG, ASTEIAN, BLAYO, HE, SHIN	N- BIPHENYLMETHYLINDOL E MODULATORS OF PPARG (PCT)
FLA 0080P	61/486,459		KAMENECKA, GRIFFIN, SHIN, HE, KOENIG, KUMAR, BURRIS KAMENECKA, GRIFFIN, SHIN,	MODULATORS OF THE NUCLEAR HORMONE RECEPTOR ROR (DISCL. NO. 11-09) (PROVISIONAL)
FLA 0092P	12/038119	WO 12/158784	HE, KOENIG, KUMAR, BURRIS, BLAYO, LYDA KAMENECKA, GRIFFIN, SHIN,	MODULATORS OF THE NUCLEAR HORMONE RECEPTOR ROR (PCT) MODULATORS OF THE NUCLEAR HORMONE RECEPTOR ROR (DISCL. NO. 11-09) (U.S. NATIONAL PHASE) [CPA-N]
FLA 0125P	14/118,116	9,586,928	HE, KOENIG, KUMAR, BURRIS, BLAYO, LYDA	CHIRAL COMPOUNDS OF VARYING CONFORMATIONAL RIGIDITY AND METHODS OF SYNTHESIS (DISCL. NO. 10-55) (PROVISIONAL)
FLA 0082P	61/531,810		MICALIZIO, KODADEK	CHIRAL COMPOUNDS OF VARYING CONFORMATIONAL RIGIDITY AND METHODS OF SYNTHESIS (CON 1)
OPK 0049P	15/972,619		MICALIZIO, KODADEK, SARKAR	CHIRAL COMPOUNDS OF VARYING CONFORMATIONAL RIGIDITY AND METHODS OF SYNTHESIS (EPO) [CPA]
OPK 0018P	12829942.7	2753175	MICALIZIO, KODADEK, SARKAR	

OPK 0016P	12/054135	WO 13/036753	MICALIZIO, KODADEK, SARKAR	CHIRAL COMPOUNDS OF VARYING CONFORMATIONAL RIGIDITY AND METHODS OF SYNTHESIS (PCT) (DISCL. NO. 12-60) CHIRAL OLIGOMERIC PENTENOATE AMIDES AS BIO-OLIGOMER MIMETICS (as amended) (U.S. NATIONAL PHASE) [CPA] N-BENZYLINDOLE MODULATORS OF PPARG (DISCL. NO. 11-05) (PROVISIONAL)
OPK 0019P	14/343,426	9,963,481	MICALIZIO, KODADEK, SARKAR	N-BENZYLINDOLE MODULATORS OF PPARG (DISCL. NO. 11-05) (PROVISIONAL)
ADI 0004P	61/493,895		KAMENECKA, GRIFFIN	N-BENZYLINDOLE MODULATORS OF PPARG (DISCL. NO. 11-05) (PROVISIONAL)
ADI 0012P	61/554,703		KAMENECKA, GRIFFIN	N-BENZYLINDOLE MODULATORS OF PPARG (DISCL. NO. 11-05) (PROVISIONAL)
ADI 0015P	61/617,138		KAMENECKA, GRIFFIN KAMENECKA, GRIFFIN,	N-BENZYLINDOLE MODULATORS OF PPARG (DISCL. NO. 11-05) (PROVISIONAL)
ADI 0018P	13/490,342	9,051,265	KOENIG, ASTEIAN, BLAYO, HE, SHIN KAMENECKA, GRIFFIN,	N-BENZYLINDOLE MODULATORS OF PPARG (DISCL. NO. 11-05) [CPA-N]
ADI 0019P	12/041137	WO 12/170561	KOENIG, ASTEIAN, BLAYO, HE, SHIN CHEN, BROTHERS, SALAH-UDDIN, BANNISTER, WAHLESTEDT	N-BENZYLINDOLE MODULATORS OF PPARG (PCT) SUBSTITUTED BENZIMIDAZOLES AS NOCICEPTIN RECEPTOR MODULATORS (DISCL. NO. 10-106) (PROVISIONAL)
FLA 0085P	61/599,610		BANNISTER, WAHLESTEDT, CHEN, BROTHERS, SALAH-UDDIN, PAN	MODULATORS (DISCL. NO. 10-106) (PROVISIONAL)
RTI 0001P	61/804,316		BANNISTER, WAHLESTEDT, CHEN, BROTHERS, SALAH-UDDIN, PAN	SUBSTITUTED BENZIMIDAZOLES AS NOCICEPTIN RECEPTOR MODULATORS (DISCL. NO. 10-106) (PROVISIONAL)
RTI 0004P	14770750.9		BANNISTER, WAHLESTEDT, CHEN, BROTHERS, SALAH-UDDIN, PAN	SUBSTITUTED BENZIMIDAZOLES AS NOCICEPTIN RECEPTOR MODULATORS (EPO) SUBSTITUTED
RTI 0002P	14/031485	WO 14/153529	BANNISTER, WAHLESTEDT, CHEN, BROTHERS,	BENZIMIDAZOLES AS NOCICEPTIN RECEPTOR MODULATORS (PCT) (DISCL. NO. 12-11)

			SALAH-UDDIN, PAN	
RTI 0003P	14/779,191	9,656,994	BANNISTER, WAHLESTEDT, CHEN, BROTHERS, SALAH-UDDIN, PAN	SUBSTITUTED BENZIMIDAZOLES AS NOCICEPTIN RECEPTOR MODULATORS (10-106) (U.S. NATIONAL PHASE) [CPA-N] SYNTHESIS OF LIBRARIES OF PEPTIDE TERTIARY AMIDES (DISCL. NO. 10- 147) (PROVISIONAL)
OPK 0005P	61/551,110		KODADEK, GAO	SYNTHESIS OF LIBRARIES OF PEPTIDE TERTIARY AMIDES (EPO) [CPA]
OPK 0020P	12844007.0	2771478	KODADEK, GAO	SYNTHESIS OF LIBRARIES OF PEPTIDE TERTIARY AMIDES (PCT)
OPK 0006P	12/061963	WO 13/063296	KODADEK, GAO	SYNTHESIS OF LIBRARIES OF PEPTIDE TERTIARY AMIDES (U.S. NATIONAL PHASE) [CPA]
OPK 0021P	14/354,031	10,370,409	KODADEK, GAO	NOVEL PHENYL GLYOXAL PROBES (DISCL. NO. 12-35) (PROVISIONAL) [BMS DOCKET NO. 12750-US-PSP] NOVEL PHENYL GLYOXAL PROBES (DISCL. NO. 12-35) (CON 1) [BMS DOCKET NO. 12750-US-CNT]
FLA 0093P	61/655,098		THOMPSON, BICKER, SUBRAMANIAN	NOVEL PHENYL GLYOXAL PROBES (EPO) [BMS DOCKET NO. 12750-EP-EPT]
PAD 0003P	15/160,079	9,921,225	THOMPSON, BICKER, SUBRAMANIAN	NOVEL PHENYL GLYOXAL PROBES (PCT) [BMS DOCKET NO. 12750-WO- PCT] NOVEL PHENYL GLYOXAL PROBES (DISCL. NO. 12-35) (U.S. NATIONAL PHASE) [BMS DOCKET NO. 12750- US-PCT]
PAD 0001P	13801428.7		THOMPSON, BICKER, SUBRAMANIAN	SMALL MOLECULES TARGETING REPEAT R(CGG) SEQUENCES (DISCL. NO. 12-33; MS 21757) (PROVISIONAL)
FLA 0109P	13/044048	WO 13/184645	THOMPSON, BICKER, SUBRAMANIAN	
PAD 0002P	14/405,467	9,347,948	THOMPSON, BICKER, SUBRAMANIAN	
FLA 0098P	61/694,977		DISNEY, LIU, CHILDS-DISNEY	

FLA 0168P	2013308578		DISNEY, LIU, CHILDS-DISNEY, YANG	SMALL MOLECULES TARGETING REPEAT R(CGG) SEQUENCES (AUSTRALIA)
FLA 0165P	2,883,320		DISNEY, LIU, CHILDS-DISNEY, YANG	SMALL MOLECULES TARGETING REPEAT R(CGG) SEQUENCES (CANADA)
ETI 0028P	15/412,231	10,011,598	DISNEY, LIU, CHILDS-DISNEY, YANG	SMALL MOLECULES TARGETING REPEAT R(CGG) SEQUENCES (DISCL. NO. 12-33) (CON 1) [CPA]
FLA 0169P	13833933.8		DISNEY, LIU, CHILDS-DISNEY, YANG	SMALL MOLECULES TARGETING REPEAT R(CGG) SEQUENCES (EPO)
FLA 0170P	1652/2015		DISNEY, LIU, CHILDS-DISNEY, YANG	SMALL MOLECULES TARGETING REPEAT R(CGG) SEQUENCES (INDIA)
FLA 0166P			DISNEY, LIU, CHILDS-DISNEY, YANG	SMALL MOLECULES TARGETING REPEAT R(CGG) SEQUENCES (JAPAN)
FLA 0171P			DISNEY, LIU, CHILDS-DISNEY, YANG	SMALL MOLECULES TARGETING REPEAT R(CGG) SEQUENCES (KOREA)
FLA 0172P	706068		DISNEY, LIU, CHILDS-DISNEY, YANG	SMALL MOLECULES TARGETING REPEAT R(CGG) SEQUENCES (NEW ZEALAND)
ETI 0062P	13/057515	WO 14/036395	DISNEY, LIU, CHILDS-DISNEY, YANG	SMALL MOLECULES TARGETING REPEAT R(CGG) SEQUENCES (PCT)
ETI 0029P	14/424,761	9,550,769	DISNEY, LIU, CHILDS-DISNEY, YANG	SMALL MOLECULES TARGETING REPEAT R(CGG) SEQUENCES (DISCL. NO. 12-33) (U.S. NATIONAL PHASE) (A-1) [CPA]
TSR 1649P	61/534,938		BOHN, PRISINZANO, AUBE, SCHOENEN, FRANKOWSKI, LI	KAPPA OPIOID RECEPTOR EFFECTORS AND USES THEREOF (DISCL. NO. 11- 65; MS 21473) (PROVISIONAL)
TSR 2014P	15/156,887	9,540,375	BOHN, PRISINZANO, AUBE, SCHOENEN, FRANKOWSKI	KAPPA OPIOID RECEPTOR EFFECTORS AND USES THEREOF (DISCL. NO. 11- 65) (CON 1)
TSR 2223P	15/401,305		BOHN, PRISINZANO, AUBE,	KAPPA OPIOID RECEPTOR EFFECTORS AND USES THEREOF (DISCL. NO. 11- 65) (CON 2)

			SCHOENEN, FRANKOWSKI	
TSR 1788P	12831982.9		BOHN, PRISINZANO, AUBE, SCHOENEN, FRANKOWSKI, LI	KAPPA OPIOID RECEPTOR EFFECTORS AND USES THEREOF (EPO)
TSR 1650P	12/055354	WO 13/040321	BOHN, PRISINZANO, AUBE, SCHOENEN, FRANKOWSKI, LI	KAPPA OPIOID RECEPTOR EFFECTORS AND USES THEREOF (PCT)
TSR 1780P	14/345,273	9,345,703	BOHN, PRISINZANO, AUBE, SCHOENEN, FRANKOWSKI	KAPPA OPIOID RECEPTOR EFFECTORS AND USES THEREOF (DISCL. NO. 11- 65) (U.S. NATIONAL PHASE)
TSR 1653P	61/279,856		SNYDER, WEI, NI, STROSBERG, KOTA, TAKAHASHI	NEW SMALL MOLECULE INHIBITORS OF HEPATITIS C VIRUS (DISCL. NO. 08- 154, 09-06) (PROVISIONAL)
TSR 1654P	10/054220	WO 11/056630	SNYDER, WEI, NI, STROSBERG, KOTA, TAKAHASHI	NEW SMALL MOLECULE INHIBITORS OF HEPATITIS C VIRUS (PCT)
TSR 1655P	13/504,822	9,174,988	SNYDER, WEI, NI, STROSBERG, KOTA, TAKAHASHI	SMALL MOLECULE INHIBITORS OF HEPATITIS C VIRUS (DISCL. NO. 08- 154, 09-06) (U.S. NATIONAL PHASE)
TAR 0001P	61/735,058		CARROLL	TARGETED COVALENT PROBES AND INHIBITORS OF PROTEINS CONTAINING REDOX- SENSITIVE CYSTEINES (DISCL. NO. 12-79) (PROVISIONAL)
TAR 0002P	13/073765	WO 14/089546	CARROLL, GUPTA	TARGETED COVALENT PROBES AND INHIBITORS OF PROTEINS CONTAINING REDOX- SENSITIVE CYSTEINES (PCT)
FLA 0183P	14/650,772	9,977,024	CARROLL, GUPTA	TARGETED COVALENT PROBES AND INHIBITORS OF PROTEINS CONTAINING REDOX- SENSITIVE CYSTEINES (DISCL. NO. 12-79) (U.S. NATIONAL PHASE)

FLA 0106P	61/768,715		PERIANA, HASHIGUCHI, BISCHOF	DIRECT, SELECTIVE PROCESSES FOR OXIDATION OF NATURAL GAS ALKANES TO ALCOHOLS (DISCL. NO. 13- 06) (PROVISIONAL)
FLA 0190P	2014218562	2014218562	PERIANA, HASHIGUCHI, BISCHOF, KONNICK	OXIDATION OF ALKANES TO ALCOHOLS (AUSTRALIA)
FLA 0191P	112015020364.7		PERIANA, HASHIGUCHI, BISCHOF, KONNICK	OXIDATION OF ALKANES TO ALCOHOLS (BRAZIL)
FLA 0192P	2,902,326	2,902,326	PERIANA, HASHIGUCHI, BISCHOF, KONNICK	OXIDATION OF ALKANES TO ALCOHOLS (CANADA)
FLA 0193P	201480010516.2		PERIANA, HASHIGUCHI, BISCHOF, KONNICK	OXIDATION OF ALKANES TO ALCOHOLS (CHINA)
FLA 0449P	202010905518.5		PERIANA, HASHIGUCHI, BISCHOF, KONNICK	OXIDATION OF ALKANES TO ALCOHOLS (CHINA/DIV 1)
FLA 0194P	150487		PERIANA, HASHIGUCHI, BISCHOF, KONNICK	OXIDATION OF ALKANES TO ALCOHOLS (ALGERIA)
FLA 0195P	201591580	030502	PERIANA, HASHIGUCHI, BISCHOF, KONNICK	OXIDATION OF ALKANES TO ALCOHOLS (EURASIA)
FLA 0196P	14753994.4	2958878	PERIANA, HASHIGUCHI, BISCHOF, KONNICK	OXIDATION OF ALKANES TO ALCOHOLS (EPO)
FLA 0197P	P-00201505156	IDP0000592 70	PERIANA, HASHIGUCHI, BISCHOF, KONNICK	OXIDATION OF ALKANES TO ALCOHOLS (INDONESIA)
FLA 0198P	7128/2015	344,364	PERIANA, HASHIGUCHI, BISCHOF, KONNICK	OXIDATION OF ALKANES TO ALCOHOLS (INDIA)
FLA 0199P	13945014000300		PERIANA, HASHIGUCHI, BISCHOF, KONNICK	OXIDATION OF ALKANES TO ALCOHOLS (IRAN)
FLA 0200P	2015/010722		PERIANA, HASHIGUCHI, BISCHOF, KONNICK	OXIDATION OF ALKANES TO ALCOHOLS (MEXICO)

FLA 0201P	PI2015702789	MY-180345-A	PERIANA, HASHIGUCHI, BISCHOF, KONNICK	OXIDATION OF ALKANES TO ALCOHOLS (MALAYSIA)
FLA 0129P	14/018175	WO 14/0130987	PERIANA, HASHIGUCHI, BISCHOF, KONNICK	OXIDATION OF ALKANES TO ALCOHOLS (PCT) (COMBINES 1560, 1583, 1584, 1585)
FLA 0202P	201508/00341		PERIANA, HASHIGUCHI, BISCHOF, KONNICK	OXIDATION OF ALKANES TO ALCOHOLS (QATAR)
FLA 0203P	14/770,039	10,745,340	PERIANA, HASHIGUCHI, BISCHOF, KONNICK	OXIDATION OF ALKANES TO ALCOHOLS (U.S. NATIONAL PHASE)
OPK 0010P	61/611,225		FAGHIHI	NATURAL ANTISENSE INHIBITION RESULTS IN TRANSCRIPTIONAL DEPRESSION AND GENE UPREGULATION (PROVISIONAL)
OPK 0011P	61/614,664		FAGHIHI, COITO	TREATMENT OF BRAIN DERIVED NEUROTROPHIC FACTOR (BDNF) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO BDNF (PROVISIONAL)
OPK 0024P	2,867,262	2,867,262	FAGHIHI, COITO	TREATMENT OF BRAIN DERIVED NEUROTROPHIC FACTOR (BDNF) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO BDNF (CANADA)
OPK 0025P	2013800248744		FAGHIHI, COITO	TREATMENT OF BRAIN DERIVED NEUROTROPHIC FACTOR (BDNF) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO BDNF (CHINA)
OPK 0055P	201910388967.4		FAGHIHI, COITO	TREATMENT OF BRAIN DERIVED NEUROTROPHIC FACTOR (BDNF) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO BDNF (CHINA/DIV 1)
OPK 0041P	15/398,630	10,214,745	FAGHIHI, COITO	TREATMENT OF BRAIN DERIVED NEUROTROPHIC FACTOR (BDNF) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE

TRANSCRIPT TO BDNF
(CON 1)

OPK 0026P	13712635.5	2825648	FAGHIHI, COITO	TREATMENT OF BRAIN DERIVED NEUROTROPHIC FACTOR (BDNF) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO BDNF (EPO)
OPK 0034P	15110742.3		FAGHIHI, COITO	TREATMENT OF BRAIN DERIVED NEUROTROPHIC FACTOR (BDNF) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO BDNF (HONG KONG)
OPK 0027P	2015-500527		FAGHIHI, COITO	TREATMENT OF BRAIN DERIVED NEUROTROPHIC FACTOR (BDNF) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO BDNF (JAPAN)
OPK 0048P	2018-016012	6738841	FAGHIHI, COITO	TREATMENT OF BRAIN DERIVED NEUROTROPHIC FACTOR (BDNF) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO BDNF (JAPAN/DIV 1)
OPK 0028P	2014-7028058		FAGHIHI, COITO	TREATMENT OF BRAIN DERIVED NEUROTROPHIC FACTOR (BDNF) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO BDNF (KOREA)
OPK 0012P	13/030589	WO 13/138374	FAGHIHI, COITO	TREATMENT OF BRAIN DERIVED NEUROTROPHIC FACTOR (BDNF) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO BDNF (PCT)
OPK 0029P	2014140112	2661104	FAGHIHI, COITO	TREATMENT OF BRAIN DERIVED NEUROTROPHIC FACTOR (BDNF) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO BDNF (RUSSIAN FEDERATION)
OPK 0030P	14/384,659		FAGHIHI, COITO	TREATMENT OF BRAIN DERIVED NEUROTROPHIC FACTOR (BDNF) RELATED

OPK 0013P	61/827,104		LOGRASSO, FENG	DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO BDNF (U.S. NATIONAL PHASE) BIDENTATE-BINDING MODULATORS OF LRRK2 AND JNK KINASES (DISCL. NO. 12-82; MS 24049) (PROVISIONAL)
OPK 0035P	14811712.0	3003302	LOGRASSO, FENG	BIDENTATE-BINDING MODULATORS OF LRRK2 AND JNK KINASES (EPO) BIDENTATE-BINDING
OPK 0022P	14/039190	WO 14/200682	LOGRASSO, FENG	MODULATORS OF LRRK2 AND JNK KINASES (PCT) BIDENTATE-BINDING
OPK 0036P	14/893,615	9,850,276	FENG, LOGRASSO	MODULATORS OF LRRK2 AND JNK KINASES (U.S. NATIONAL PHASE) DIRECT, SELECTIVE PROCESSES FOR OXIDATION OF NATURAL GAS ALKANES TO ALCOHOLS WITH SELENIUM, TELLURIUM, AND HYPERVALENT
FLA 0113P	61/862,715		PERIANA, KONNICK, HASHIGUCHI	IODINE REAGENTS (DISCL. NO. 13-43) (PROVISIONAL) (SEE 1560.1 PC) DIRECT, SELECTIVE PROCESSES FOR BISMUTH MEDIATED OXIDATION OF NATURAL GAS ALKANES TO ALCOHOLS WITH BI(V)
FLA 0114P	61/862,723		PERIANA, KONNICK, HASHIGUCHI	REGENERATION (DISCL. NO. 13-44) (PROVISIONAL) (SEE 1560.1 PC) DIRECT, SELECTIVE PROCESS FOR LEAD MEDIATED OXIDATION OF NATURAL GAS ALKANES WITH Pb(IV)
FLA 0115P	61/862,731		PERIANA, KONNICK, HASHIGUCHI	REGENERATION (DISCL. NO. 13-45) (PROVISIONAL) (SEE 1560.1 PC) PROCESSES FOR DIRECT CONVERSION OF ALKANES TO FUNCTIONALIZED INTERMEDIATES WITH SELENIUM AND
FLA 0116P	61/862,732		PERIANA, KONNICK, HASHIGUCHI	TELLURIUM REAGENTS (DISCL. NO. 13-46) (PROVISIONAL)

FLA 0215P	2014306055	2014306055	PERIANA, KONNICK, HASHIGUCHI	CONVERSION OF ALKANES TO ORGANOSELENIUMS AND ORGANOTELLURIUMS (AUSTRALIA)
FLA 0216P	2,919,659	2,919,659	PERIANA, KONNICK, HASHIGUCHI	CONVERSION OF ALKANES TO ORGANOSELENIUMS AND ORGANOTELLURIUMS (CANADA)
FLA 0217P	201480050688.2	2014800506 88.2	PERIANA, KONNICK, HASHIGUCHI	CONVERSION OF ALKANES TO ORGANOSELENIUMS AND ORGANOTELLURIUMS (CHINA)
FLA 0241P	15/362,335		PERIANA, KONNICK, HASHIGUCHI	CONVERSION OF ALKANES TO ORGANOSELENIUMS AND ORGANOTELLURIUMS (DISCL. NO. 13-46) (CON 1)
FLA 0218P	201690344	032269	PERIANA, KONNICK, HASHIGUCHI	CONVERSION OF ALKANES TO ORGANOSELENIUMS AND ORGANOTELLURIUMS (EURASIA)
FLA 0219P	14833997.1	3030635	PERIANA, KONNICK, HASHIGUCHI	CONVERSION OF ALKANES TO ORGANOSELENIUMS AND ORGANOTELLURIUMS (EPO)
FLA 0138P	14/049903	WO 15/021126	PERIANA, KONNICK, HASHIGUCHI	CONVERSION OF ALKANES TO ORGANOSELENIUMS AND ORGANOTELLURIUMS (PCT)
FLA 0220P	14/910,275	9,505,714	PERIANA, KONNICK, HASHIGUCHI	CONVERSION OF ALKANES TO ORGANOSELENIUMS AND ORGANOTELLURIUMS (DISCL. NO. 13-46) (U.S. NATIONAL PHASE)
FLA 0117P	61/846,204		DISNEY, GUAN	PROGRAMMABLE, COVALENT RNA-SMALL MOLECULE ADDUCT FORMATION ENABLES CELLULAR PROFILING OF RNA-SMALL MOLECULE INTERACTIONS (DISCL. NO. 13-52; MS 24075) (PROVISIONAL)
ETI 0010P	2014290206	2014290206	DISNEY, GUAN, YANG	SPECIFIC TARGETING OF RNA EXPANDED REPEAT SEQUENCES (AUSTRALIA) [CPA]

ETI 0024P	15/427,288	9,933,419	DISNEY, GUAN, YANG	SPECIFIC TARGETING OF RNA EXPANDED REPEAT SEQUENCES (DISCL. NO. 13-52) (CON 1) [CPA] SPECIFIC TARGETING OF RNA EXPANDED REPEAT SEQUENCES (DISCL. NO. 13-52) (CON 2)
ETI 0036P	15/915,765		DISNEY, GUAN, YANG	
ETI 0001P	14825696.9	3022219	DISNEY, GUAN, YANG	SPECIFIC TARGETING OF RNA EXPANDED REPEAT SEQUENCES (EPO)
ETI 0020P	14/046626	WO 15/009678	DISNEY, GUAN, YANG	SPECIFIC TARGETING OF RNA EXPANDED REPEAT SEQUENCES (PCT) SPECIFIC TARGETING OF RNA EXPANDED REPEAT SEQUENCES (DISCL. NO. 13-52) (U.S. NATIONAL PHASE) [CPA] (A-1, A-2)
ETI 0002P	14/904,999	9,586,944	DISNEY, GUAN, YANG	TRANSCRIPTOME-WIDE DESIGN OF SELECTIVE, BIOACTIVE SMALL MOLECULES TARGETING RNA (DISCL. NO. 13-61; MS 22033, 24099)
FLA 0118P	61/864,081		DISNEY, VELAGAPUDI	(PROVISIONAL) TRANSCRIPTOME-WIDE DESIGN OF SELECTIVE, BIOACTIVE SMALL MOLECULES TARGETING RNA (DISCL. NO. 13-61)
ETI 0023P	16/214,327		DISNEY, VELAGAPUDI	(DIV 1) TRANSCRIPTOME-WIDE DESIGN OF SELECTIVE, BIOACTIVE SMALL MOLECULES TARGETING RNA (EPO)
FLA 0229P	14752771.7	3030548	DISNEY, VELAGAPUDI	TRANSCRIPTOME-WIDE DESIGN OF SELECTIVE, BIOACTIVE SMALL MOLECULES TARGETING RNA (EPO/DIV 1) [CPA]
ETI 0025P	17182525.0		DISNEY, VELAGAPUDI	TRANSCRIPTOME-WIDE DESIGN OF SELECTIVE, BIOACTIVE SMALL MOLECULES TARGETING RNA (HONG KONG)
ETI 0040P	18111859.7		DISNEY, VELAGAPUDI	TRANSCRIPTOME-WIDE DESIGN OF SELECTIVE, BIOACTIVE SMALL MOLECULES TARGETING RNA (PCT)
ETI 0021P	14/050399	WO 15/021415	DISNEY, VELAGAPUDI	

ETI 0004P	14/911,032	10,157,261	DISNEY, VELAGAPUDI	TRANSCRIPTOME-WIDE DESIGN OF SELECTIVE, BIOACTIVE SMALL MOLECULES TARGETING RNA (DISCL. NO. 13-61) (U.S. NATIONAL PHASE) [CPA] MODULARLY ASSEMBLED SMALL MOLECULES FOR THE TREATMENT OF MYOTONIC DYSTROPHY TYPE 1 (DISCL. NO. 13-63; MS 25047) (PROVISIONAL)
FLA 0119P	61/871,483		DISNEY, RZUCZEK	MODULARLY ASSEMBLED SMALL MOLECULES FOR THE TREATMENT OF MYOTONIC DYSTROPHY TYPE 1 (CON 1)
ETI 0027P	15/692,675		DISNEY, RZUCZEK	MODULARLY ASSEMBLED SMALL MOLECULES FOR THE TREATMENT OF MYOTONIC DYSTROPHY TYPE 1 (EPO) [CPA] (A-2)
ETI 0005P	14841286.9	3038637	DISNEY, RZUCZEK	MODULARLY ASSEMBLED SMALL MOLECULES FOR THE TREATMENT OF MYOTONIC DYSTROPHY TYPE 1 (EPO/DIV 1)
ETI 0046P			DISNEY, RZUCZEK	MODULARLY ASSEMBLED SMALL MOLECULES FOR THE TREATMENT OF MYOTONIC DYSTROPHY TYPE 1 (PCT)
ETI 0022P	14/053520	WO 15/031819	DISNEY, RZUCZEK	MODULARLY ASSEMBLED SMALL MOLECULES FOR THE TREATMENT OF MYOTONIC DYSTROPHY TYPE 1 (U.S. NATIONAL PHASE) [CPA] (A-1, A-2)
ETI 0006P	14/915,439	9,795,687	DISNEY, RZUCZEK	CYCLIC PEPTIDE CONJUGATES AND METHODS OF USE (DISCL. NO. 13-85) (PROVISIONAL)
TSR 1742P	61/883,910		HAZLEHURST, RADER, LI, MCLAUGHLIN	CYCLIC PEPTIDE CONJUGATES AND METHODS OF USE (DISCL. NO. 13-85) (U.S. NATIONAL PHASE)
TSR 2540P	16/025,382	11,078,235	HAZLEHURST, RADER, LI, MCLAUGHLIN	CYCLIC PEPTIDE CONJUGATES AND METHODS OF USE (PCT)
TSR 1832P	14/057763	WO 15/048477	HAZLEHURST, RADER, LI, MCLAUGHLIN	CYCLIC PEPTIDE CONJUGATES AND METHODS OF USE (DISCL.
TSR 1991P	15/024,928	10,011,635	HAZLEHURST, RADER, LI, MCLAUGHLIN	

				NO. 13-85) (U.S. NATIONAL PHASE)
				SCREENING METHODS FOR AND SMALL MOLECULE ANALOGS OF THE NEMO BINDING PEPTIDE THAT INHIBIT INDUCIBLE I KAPPA B KINASE (IKK) FOR REGULATION OF NF-KAPPA B (DISCL. NO. 13-100) (PROVISIONAL)
FLA 0126P	61/973,669		ROBBINS, NIEDERNHOFER, KAMENECKA, WILSON	SCREENING METHODS FOR AND SMALL MOLECULE ANALOGS OF THE NEMO BINDING PEPTIDE THAT INHIBIT INDUCIBLE I KAPPA B KINASE (IKK) FOR REGULATION OF NF-KAPPA B (DISCL. NO. 13-100) (PROVISIONAL)
FLA 0127P	62/169,266		ROBBINS, NIEDERNHOFER, KAMENECKA, WILSON	SCREENING METHODS FOR AND SMALL MOLECULE ANALOGS OF THE NEMO BINDING PEPTIDE THAT INHIBIT INDUCIBLE IKB KINASE (IKK) FOR REGULATION OF NF-KB (PROVISIONAL)
FLA 0303P	2,988,421		ROBBINS, NIEDERNHOFER, KAMENECKA, WILSON	SMALL MOLECULE ANALOGS OF THE NEMO BINDING PEPTIDE (CANADA)
FLA 0304P	16804029.3		ROBBINS, NIEDERNHOFER, KAMENECKA, WILSON	SMALL MOLECULE ANALOGS OF THE NEMO BINDING PEPTIDE (EPO)
FLA 0305P			ROBBINS, NIEDERNHOFER, KAMENECKA, WILSON	SMALL MOLECULE ANALOGS OF THE NEMO BINDING PEPTIDE (JAPAN)
FLA 0235P	16/034083	WO 16/196117	ROBBINS, NIEDERNHOFER, KAMENECKA, WILSON	SMALL MOLECULE ANALOGS OF THE NEMO BINDING PEPTIDE (PCT)
FLA 0306P	15/579,103	10,758,522	ROBBINS, NIEDERNHOFER, KAMENECKA, WILSON	SMALL MOLECULE ANALOGS OF THE NEMO BINDING PEPTIDE (U.S. NATIONAL PHASE) [CPA-N]
FLA 0131P	61/980,444		GRIFFIN, KAMENECKA	PPARG MODULATORS FOR TREATMENT OF OSTEOPOROSIS (DISCL. NO. 14-28) (PROVISIONAL)
FLA 0344P	16/028,730	10,744,117	GRIFFIN, KAMENECKA, LECKA-CZERNIK	PPARG MODULATORS FOR THE TREATMENT OF OSTEOPOROSIS (CON 1)
FLA 0430P	16/909,324		GRIFFIN, KAMENECKA, LECKA-CZERNIK	PPARG MODULATORS FOR THE TREATMENT OF OSTEOPOROSIS (CON 2)
FLA 0465P	17/168,690		GRIFFIN, KAMENECKA, LECKA-CZERNIK	PPARG MODULATORS FOR THE TREATMENT OF OSTEOPOROSIS (CON 3)

FLA 0485P	17/478,235		GRIFFIN, KAMENECKA, LECKA-CZERNIK	PPARG MODULATORS FOR THE TREATMENT OF OSTEOPOROSIS (CON 4)
FLA 0164P	15/026226	WO 15/161108	GRIFFIN, KAMENECKA, LECKA-CZERNIK	PPARG MODULATORS FOR THE TREATMENT OF OSTEOPOROSIS (PCT)
FLA 0244P	15/302,862	10,016,394	GRIFFIN, KAMENECKA, LECKA-CZERNIK	PPARG MODULATORS FOR TREATMENT OF OSTEOPOROSIS (DISCL. NO. 14-28) (U.S. NATIONAL PHASE)
NBE 0001P	62/280,834		RADER, PENG, LI	ROR2 ANTIBODY COMPOSITIONS AND RELATED METHODS (DISCL. NO. 13-53, 14-53, 15- 37) (PROVISIONAL)
NBE 0006P	2017209313		RADER, PENG, LI	ROR2 ANTIBODY COMPOSITIONS AND RELATED METHODS (AUSTRALIA)
NBE 0007P	3,011,817		RADER, PENG, LI	ROR2 ANTIBODY COMPOSITIONS AND RELATED METHODS (CANADA)
NBE 0008P	201780018525.X		RADER, PENG, LI	ROR2 ANTIBODY COMPOSITIONS AND RELATED METHODS (CHINA)
NBE 0039P	17/382,948		RADER, PENG, LI	ROR2 ANTIBODY COMPOSITIONS AND RELATED METHODS (DIV 1)
NBE 0009P	17702284.5		RADER, PENG, LI	ROR2 ANTIBODY COMPOSITIONS AND RELATED METHODS (EPO)
NBE 0010P	260688		RADER, PENG, LI	ROR2 ANTIBODY COMPOSITIONS AND RELATED METHODS (ISRAEL)
NBE 0011P	201827029864		RADER, PENG, LI	ROR2 ANTIBODY COMPOSITIONS AND RELATED METHODS (INDIA)
NBE 0012P	2018-537772		RADER, PENG, LI	ROR2 ANTIBODY COMPOSITIONS AND RELATED METHODS (JAPAN)
NBE 0013P	2018-7023610		RADER, PENG, LI	ROR2 ANTIBODY COMPOSITIONS AND RELATED METHODS (KOREA)
NBE 0014P	744574		RADER, PENG, LI	ROR2 ANTIBODY COMPOSITIONS AND RELATED METHODS (NEW ZEALAND)

NBE 0003P	17/014370	WO 17/127702	RADER, PENG, LI	ROR2 ANTIBODY COMPOSITIONS AND RELATED METHODS (PCT)
NBE 0015P	11201806121P		RADER, PENG, LI	ROR2 ANTIBODY COMPOSITIONS AND RELATED METHODS (SINGAPORE)
NBE 0016P	16/071,361	11,078,273	RADER, PENG, LI	ROR2 ANTIBODY COMPOSITIONS AND RELATED METHODS (U.S. NATIONAL PHASE)
NBE 0017P	2018/04850		RADER, PENG, LI	ROR2 ANTIBODY COMPOSITIONS AND RELATED METHODS (SOUTH AFRICA)
FLA 0134P	62/026,266		DISNEY, RZUCZEK	A TOXIC RNA CATALYZES THE IN CELLULO SYNTHESIS OF ITS OWN INHIBITOR (DISCL. NO. 14- 55; MS 28024)
ETI 0012P	2015289524		DISNEY, RZUCZEK	(PROVISIONAL) TOXIC RNA INHIBITORS SELF-ASSEMBLED IN SITU (AUSTRALIA)
ETI 0013P	2,955,428		DISNEY, RZUCZEK	TOXIC RNA INHIBITORS SELF-ASSEMBLED IN SITU (CANADA)
ETI 0014P	201580050560.0		DISNEY, RZUCZEK	TOXIC RNA INHIBITORS SELF-ASSEMBLED IN SITU (CHINA)
ETI 0048P	16/266,832	10,471,057	DISNEY, RZUCZEK	TOXIC RNA INHIBITORS SELF-ASSEMBLED IN SITU (DISCL. NO. 14-55) (DIV 1) [CPA]
ETI 0015P	15822000.4		DISNEY, RZUCZEK	TOXIC RNA INHIBITORS SELF-ASSEMBLED IN SITU (EPO)
ETI 0026P	17106538.7		DISNEY, RZUCZEK	TOXIC RNA INHIBITORS SELF-ASSEMBLED IN SITU (HONG KONG)
ETI 0016P	250113		DISNEY, RZUCZEK	TOXIC RNA INHIBITORS SELF-ASSEMBLED IN SITU (ISRAEL)
ETI 0017P	2017-502695	6461306	DISNEY, RZUCZEK	TOXIC RNA INHIBITORS SELF-ASSEMBLED IN SITU (JAPAN) [CPA]
ETI 0049P	2018-241478		DISNEY, RZUCZEK	TOXIC RNA INHIBITORS SELF-ASSEMBLED IN SITU (JAPAN/DIV 1)

ETI 0007P	15/040902	WO 16/011348	DISNEY, RZUCZEK	TOXIC RNA INHIBITORS SELF-ASSEMBLED IN SITU (PCT)
ETI 0018P	11201700387Q		DISNEY, RZUCZEK	TOXIC RNA INHIBITORS SELF-ASSEMBLED IN SITU (SINGAPORE)
ETI 0019P	15/327,117	10,220,031	DISNEY, RZUCZEK	TOXIC RNA INHIBITORS SELF-ASSEMBLED IN SITU (DISCL. NO. 14-55) (U.S. NATIONAL PHASE) [CPA] (A-1, A-2)
FLA 0136P	62/016,292		SHEN	STRAIN PRIORITIZATION FOR NATURAL PRODUCT DISCOVERY BY A HIGH- THROUGHPUT REAL-TIME PCR METHOD (DISCL. NO. 14-61; MS 27084) (PROVISIONAL)
FLA 0158P	62/100,932		SHEN	ANTICANCER DRUG CANDIDATES (DISCL. NO. 14-97; MS 29012) (PROVISIONAL)
FLA 0182P	15/037455	WO 15/200501	SHEN	STRAIN PRIORITIZATION FOR NATURAL PRODUCT DISCOVERY BY A HIGH- THROUGHPUT REAL-TIME PCR METHOD (PCT) (1654.0)
FLA 0280P	201680014362.3		SHEN	ANTICANCER DRUG CANDIDATES (CHINA)
FLA 0368P	16/439,300		SHEN	ANTICANCER DRUG CANDIDATES (CON 1)
FLA 0214P	16/012634	WO 16/112282	SHEN	ANTICANCER DRUG CANDIDATES (PCT)
FLA 0281P	15/541,904	10,336,766	SHEN	ANTICANCER DRUG CANDIDATES (U.S. NATIONAL PHASE)
FLA 0140P	62/041,270		PERIANA, KONNICK, HASHIGUCHI	PROCESS FOR OXIDATION OF HETEROALKANES (DISCL. NO. 14-65, 14-68) (PROVISIONAL)
FLA 0273P	2015306741	2015306741	PERIANA, KONNICK, HASHIGUCHI	PROCESS FOR THE FUNCTIONALIZATION OF HETEROALKANES AND ARENES (AUSTRALIA)
FLA 0263P	112017003912-5	1120170039 12-5	PERIANA, KONNICK, HASHIGUCHI	PROCESS FOR THE FUNCTIONALIZATION OF HETEROALKANES AND ARENES (BRAZIL)
FLA 0272P	2,958,425		PERIANA, KONNICK, HASHIGUCHI	PROCESS FOR THE FUNCTIONALIZATION OF HETEROALKANES AND ARENES (CANADA)

FLA 0267P	2015800459975		PERIANA, KONNICK, HASHIGUCHI	PROCESS FOR THE FUNCTIONALIZATION OF HETEROALKANES AND ARENES (CHINA)
FLA 0268P	201790467		PERIANA, KONNICK, HASHIGUCHI	PROCESS FOR THE FUNCTIONALIZATION OF HETEROALKANES AND ARENES (EURASIA)
FLA 0251P	15763687.9		PERIANA, KONNICK, HASHIGUCHI	PROCESS FOR THE FUNCTIONALIZATION OF HETEROALKANES AND ARENES (EPO)
FLA 0274P	201717005657		PERIANA, KONNICK, HASHIGUCHI	PROCESS FOR THE FUNCTIONALIZATION OF HETEROALKANES AND ARENES (INDIA)
FLA 0269P	2017/002118		PERIANA, KONNICK, HASHIGUCHI	PROCESS FOR THE FUNCTIONALIZATION OF HETEROALKANES AND ARENES (MEXICO)
FLA 0204P	15/046721	WO 16/033061	PERIANA, KONNICK, HASHIGUCHI	PROCESS FOR THE FUNCTIONALIZATION OF HETEROALKANES AND ARENES (PCT) [COMBINES 1657.0 AND 1658.0]
FLA 0264P	15/506,583	10,011,547	PERIANA, KONNICK, HASHIGUCHI	PROCESS FOR THE FUNCTIONALIZATION OF HETEROALKANES AND ARENES (U.S. NATIONAL PHASE)
FLA 0141P	62/042,101		PERIANA, KONNICK, HASHIGUCHI	PROCESS FOR OXIDATION OF ARENES (DISCL. NO. 14- 65, 14-68, 14-80) (PROVISIONAL) [SEE 1657.1 PC]
FLA 0142P	62/042,099		KOUBA, PIETSCH	PRODUCT SEPARATION FROM HYDROCARBON OXIDATION (DISCL. NO. 14-65) (PROVISIONAL)
FLA 0265P	2015800459782		KOUBA, PIETSCH	RECOVERY PROCESS FOR FUNCTIONALIZED COMPOUND REACTION PRODUCT (CHINA)
FLA 0252P	15762857.9		KOUBA, PIETSCH	RECOVERY PROCESS FOR FUNCTIONALIZED COMPOUND REACTION PRODUCT (EPO)
FLA 0206P	15/046935	WO 16/033174	KOUBA, PIETSCH	RECOVERY PROCESS FOR FUNCTIONALIZED COMPOUND REACTION PRODUCT (PCT)

FLA 0266P	15/506,611	10,654,790	KOUBA, PIETSCH	RECOVERY PROCESS FOR FUNCTIONALIZED COMPOUND REACTION PRODUCT (U.S. NATIONAL PHASE)
FLA 0144P	62/036,721		DISNEY	TREATMENT OF C9FTD/ALS BY TARGETING RNA EXPANDED REPEAT SEQUENCES (DISCL. NO. 14-70; MS 28018) (PROVISIONAL)
ETI 0035P	2,990,161		DISNEY	TREATMENT OF C9FTD/ALS BY TARGETING RNA EXPANDED REPEAT SEQUENCES (CANADA)
ETI 0039P	15/969,374	10,465,196	DISNEY	TREATMENT OF C9FTD/ALS BY TARGETING RNA EXPANDED REPEAT SEQUENCES (CON 1) [CPA]
ETI 0061P			DISNEY	TREATMENT OF C9FTD/ALS BY TARGETING RNA EXPANDED REPEAT SEQUENCES (DIV 1)
FLA 0188P	15/045021	WO 16/025692	DISNEY	TREATMENT OF C9FTD/ALS BY TARGETING RNA EXPANDED REPEAT SEQUENCES (PCT)
ETI 0031P	11201709204V		DISNEY	TREATMENT OF C9FTD/ALS BY TARGETING RNA EXPANDED REPEAT SEQUENCES (SINGAPORE)
ETI 0030P	15/503,524		DISNEY	TREATMENT OF C9FTD/ALS BY TARGETING RNA EXPANDED REPEAT SEQUENCES (U.S. NATIONAL PHASE) (A-1)
FLA 0150P	62/037,434		SIEGEL, MILONE, KACIR, RADER	GLYCOSYL-PHOSPHATIDYLINOSITOL (GPI)-LINKED GDNF FAMILY ALPHA-RECEPTOR 4 (GFR ALPHA 4)-SPECIFIC ANTIBODY AND USES THEREOF (DISCL. NO. 14-81) (PROVISIONAL)
FLA 0275P	62/037,383		SIEGEL, MILONE, BHOJ, RADER	CAR-T CELL THERAPY FOR MEDULLARY

				THYROID CARCINOMA (PROVISIONAL)
				GLYCOSYL- PHOSPHATIDYLINOSITOL (GPI)-LINKED GDNF FAMILY ALPHA- RECEPTOR 4 (GFR ALPHA 4)-SPECIFIC ANTIBODY AND USES THEREOF (PCT) TREATMENT OF CANCER USING GFR ALPHA-4
FLA 0208P	15/045355	WO 16/025884	SIEGEL, MILONE, KACIR, RADER	
FLA 0258P	2015301460	2015301460	SIEGEL, MILONE, BHOJ, RADER	CHIMERIC ANTIGEN RECEPTOR (AUSTRALIA) TREATMENT OF CANCER USING GFR ALPHA-4 CHIMERIC ANTIGEN RECEPTOR (AUSTRALIA/DIV 1) TREATMENT OF CANCER USING GFR ALPHA-4 CHIMERIC ANTIGEN RECEPTOR (CANADA)
FLA 0477P	2021203514		SIEGEL, MILONE, BHOJ, RADER	
FLA 0259P	2,958,200		SIEGEL, MILONE, BHOJ, RADER	
FLA 0461P	17/078,903		SIEGEL, MILONE, BHOJ, RADER	TREATMENT OF CANCER USING GFR ALPHA-4 CHIMERIC ANTIGEN RECEPTOR (DISCL. NO. 14- 81) (DIV 1)
FLA 0260P	15757371.8		SIEGEL, MILONE, BHOJ, RADER	TREATMENT OF CANCER USING GFR ALPHA-4 CHIMERIC ANTIGEN RECEPTOR (EPO)
FLA 0308P	17113522.1		SIEGEL, MILONE, BHOJ, RADER	TREATMENT OF CANCER USING GFR ALPHA-4 CHIMERIC ANTIGEN RECEPTOR (HONG KONG)
FLA 0261P	2017-508039	6919118	SIEGEL, MILONE, BHOJ, RADER	TREATMENT OF CANCER USING GFR ALPHA-4 CHIMERIC ANTIGEN RECEPTOR (JAPAN) TREATMENT OF CANCER USING GFR ALPHA-4 CHIMERIC ANTIGEN RECEPTOR (DISCL. NO. 14- 81) (PCT) TREATMENT OF CANCER USING GFR ALPHA-4 CHIMERIC ANTIGEN RECEPTOR (DISCL. NO. 14-
FLA 0257P	15/045349	WO 16/025880	SIEGEL, MILONE, BHOJ, RADER	
FLA 0262P	15/503,971	10,851,149	SIEGEL, MILONE, BHOJ, RADER	

				81) (U.S. NATIONAL PHASE)
FLA 0152P	62/059,423		BANNISTER, BOHN, SCHMID, ROSS, LOVELL	SIGNALING-BIASED MU OPIOID RECEPTOR AGONISTS (DISCL. NO. 14-51) (PROVISIONAL)
FLA 0212P	62/308,333		BANNISTER, BOHN, SCHMID	SIGNALING-BIASED MU OPIOID RECEPTOR AGONISTS (DISCL. NO. 14-51) (PROVISIONAL)
FLA 0346P	17714106.6		BANNISTER, BOHN, SCHMID	SIGNALING-BIASED MU OPIOID RECEPTOR AGONISTS (EPO)
FLA 0276P	17/022552	WO 17/161017	BANNISTER, BOHN, SCHMID	SIGNALING-BIASED MU OPIOID RECEPTOR AGONISTS (PCT)
FLA 0347P	16/085,100	10,751,335	BANNISTER, BOHN, SCHMID	SIGNALING-BIASED MU OPIOID RECEPTOR AGONISTS (U.S. NATIONAL PHASE)
FLA 0153P	62/106,465		BANNISTER, WANG, WANG	CHROMENONE INHIBITORS OF MONOCARBOXYLATE TRANSPORTERS (DISCL. NO. 14-90) (PROVISIONAL)
FLA 0282P	2,974,694		BANNISTER, WANG, WANG, CLEVELAND	CHROMENONE INHIBITORS OF MONOCARBOXYLATE TRANSPORTERS (CANADA) [CPA-N]
FLA 0283P	16740815.2	3247349	BANNISTER, WANG, WANG, CLEVELAND	CHROMENONE INHIBITORS OF MONOCARBOXYLATE TRANSPORTERS (EPO) [CPA-N]
FLA 0284P	2017-538317	6713472	BANNISTER, WANG, WANG, CLEVELAND	CHROMENONE INHIBITORS OF MONOCARBOXYLATE TRANSPORTERS (JAPAN) [CPA-N]
FLA 0222P	16/014455	WO 16/118822	BANNISTER, WANG, WANG, CLEVELAND	CHROMENONE INHIBITORS OF MONOCARBOXYLATE TRANSPORTERS (PCT)
FLA 0285P	15/545,117	9,994,555	BANNISTER, H. WANG, C. WANG, CLEVELAND	CHROMENONE INHIBITORS OF MONOCARBOXYLATE TRANSPORTERS (U.S. NATIONAL PHASE)
FLA 0155P	62/106,472		BANNISTER, WANG, WANG	PTERIDINE DIONE MONOCARBOXYLATE TRANSPORTER INHIBITORS (DISCL. NO. 14-92) (PROVISIONAL)

FLA 0286P	2,974,696		BANNISTER, WANG, WANG, CLEVELAND	PTERIDINE DIONE MONOCARBOXYLATE TRANSPORTER INHIBITORS (CANADA) [CPA-N]
FLA 0359P	16/423,362	10,874,675	BANNISTER, H. WANG, C. WANG, CLEVELAND	PTERIDINE DIONE MONOCARBOXYLATE TRANSPORTER INHIBITORS (DIV 1) PTERIDINE DIONE MONOCARBOXYLATE TRANSPORTER INHIBITORS (EPO) [CPA-N]
FLA 0287P	16740816.0		BANNISTER, WANG, WANG, CLEVELAND	PTERIDINE DIONE MONOCARBOXYLATE TRANSPORTER INHIBITORS (JAPAN) [CPA- N]
FLA 0288P	2017-538316	6612882	BANNISTER, WANG, WANG, CLEVELAND	PTERIDINE DIONE MONOCARBOXYLATE TRANSPORTER INHIBITORS (PCT) PTERIDINE DIONE MONOCARBOXYLATE TRANSPORTER INHIBITORS (U.S. NATIONAL PHASE) [CPA- N]
FLA 0223P	16/014458	WO 16/118823	BANNISTER, WANG, WANG, CLEVELAND	HETEROCYCLIC INHIBITORS OF MONOCARBOXYLATE TRANSPORTERS (DISCL. NO. 14-93) (PROVISIONAL)
FLA 0289P	15/545,152	10,328,078	BANNISTER, H. WANG, C. WANG, CLEVELAND	HETEROCYCLIC INHIBITORS OF MONOCARBOXYLATE TRANSPORTERS (CANADA) [CPA-N]
FLA 0156P	62/106,479		BANNISTER, ROUSH, CHOI, NAIR, TSAI, MISHRA BANNISTER, ROUSH, CHOI, NAIR, TSAI, MISHRA, CLEVELAND	HETEROCYCLIC INHIBITORS OF MONOCARBOXYLATE TRANSPORTERS (CON 1)
FLA 0290P	2,974,697		BANNISTER, ROUSH, CHOI, NAIR, TSAI, MISHRA, CLEVELAND	HETEROCYCLIC INHIBITORS OF MONOCARBOXYLATE TRANSPORTERS (CON 2)
FLA 0369P	16/439,950	10,851,113	BANNISTER, ROUSH, CHOI, NAIR, TSAI, MISHRA, CLEVELAND	HETEROCYCLIC INHIBITORS OF MONOCARBOXYLATE TRANSPORTERS (EPO) [CPA-N]
FLA 0463P	16/949,983		BANNISTER, ROUSH, CHOI, NAIR, TSAI, MISHRA, CLEVELAND	
FLA 0291P	16740818.6	3247360	BANNISTER, ROUSH, CHOI, NAIR, TSAI, MISHRA, CLEVELAND	

FLA 0292P	2017-538322	6725519	BANNISTER, ROUSH, CHOI, NAIR, TSAI, MISHRA, CLEVELAND	HETEROCYCLIC INHIBITORS OF MONOCARBOXYLATE TRANSPORTERS (JAPAN) [CPA-N]
FLA 0224P	16/014461	WO 16/118825	BANNISTER, ROUSH, CHOI, NAIR, TSAI, MISHRA, CLEVELAND	HETEROCYCLIC INHIBITORS OF MONOCARBOXYLATE TRANSPORTERS (PCT) HETEROCYCLIC INHIBITORS OF MONOCARBOXYLATE TRANSPORTERS (U.S. NATIONAL PHASE) [CPA- N]
FLA 0293P	15/545,168	10,329,303	BANNISTER, ROUSH, CHOI, NAIR, TSAI, MISHRA, CLEVELAND	METHODS AND COMPOSITIONS FOR PROTECTION AGAINST LENTIVIRAL INFECTIONS (DISCL. NO. 14-102; MS 29017) (PROVISIONAL)
EMM 0001P	62/153,731		GARDNER, FARZAN	METHODS AND COMPOSITIONS FOR PROTECTION AGAINST LENTIVIRAL INFECTIONS (DISCL. NO. 14-102) [CPA]
EMM 0002P	15/140,919	10,626,161	GARDNER, FARZAN	METHODS AND COMPOSITIONS FOR PROTECTION AGAINST LENTIVIRAL INFECTIONS (DIV 1)
EMM 0009P	16/787,870		GARDNER, FARZAN	HDAC INHIBITOR COMPOUNDS AND METHODS OF TREATMENT (DISCL. NO. 13-76) (PROVISIONAL)
TSR 1872P	61/975,564		LIAO, ROUSH, STOWE	HDAC INHIBITOR COMPOUNDS AND METHODS OF TREATMENT (DISCL. 13-76) (PROVISIONAL)
TSR 1873P	62/117,326		LIAO, ROUSH, STOWE	HDAC INHIBITOR COMPOUNDS AND METHODS OF TREATMENT (CON 1)
TSR 2460P	17/000,180		LIAO, ROUSH, STOWE	HDAC INHIBITOR COMPOUNDS AND METHODS OF TREATMENT (PCT)
TSR 1874P	15/023437	WO 15/153516	LIAO, ROUSH, STOWE	HDAC INHIBITOR COMPOUNDS AND METHODS OF TREATMENT (U.S. NATIONAL PHASE)
TSR 2049P	15/301,508	10,807,944	LIAO, ROUSH, STOWE	

NBE 0002P	62/280,843		RADER, PENG RADER, PENG, BEERLI, WALDMEIER, GRAWUNDER	ROR1 ANTIBODY COMPOSITIONS AND RELATED METHODS (DISCL. NO. 15-33) (PROVISIONAL)
NBE 0035P	16/040,244	10,618,959	RADER, PENG, BEERLI, WALDMEIER, GRAWUNDER	ROR1 ANTIBODY COMPOSITIONS AND RELATED METHODS [CPA]
NBE 0018P	2017210327		RADER, PENG, BEERLI, WALDMEIER, GRAWUNDER	ROR1 ANTIBODY COMPOSITIONS AND RELATED METHODS (AUSTRALIA) [CPA]
NBE 0019P	112018014615-3		RADER, PENG, BEERLI, WALDMEIER, GRAWUNDER	ROR1 ANTIBODY COMPOSITIONS AND RELATED METHODS (BRAZIL) [CPA]
NBE 0020P	3,011,815		RADER, PENG, BEERLI, WALDMEIER, GRAWUNDER	ROR1 ANTIBODY COMPOSITIONS AND RELATED METHODS (CANADA) [CPA]
NBE 0021P	2018-01971		RADER, PENG, BEERLI, WALDMEIER, GRAWUNDER	ROR1 ANTIBODY COMPOSITIONS AND RELATED METHODS (CHILE) [CPA]
NBE 0022P	201780019846.1		RADER, PENG, BEERLI, WALDMEIER, GRAWUNDER	ROR1 ANTIBODY COMPOSITIONS AND RELATED METHODS (CHINA) [CPA]
NBE 0038P	16/805,102		RADER, PENG, BEERLI, WALDMEIER, GRAWUNDER	ROR1 ANTIBODY COMPOSITIONS AND RELATED METHODS (CON 1)
NBE 0023P	17703552.4		RADER, PENG, BEERLI, WALDMEIER, GRAWUNDER	ROR1 ANTIBODY COMPOSITIONS AND RELATED METHODS (EPO) [CPA]
NBE 0024P			RADER, PENG, BEERLI, WALDMEIER, GRAWUNDER	ROR1 ANTIBODY COMPOSITIONS AND RELATED METHODS (HONG KONG)
NBE 0025P	260689		RADER, PENG, BEERLI, WALDMEIER, GRAWUNDER	ROR1 ANTIBODY COMPOSITIONS AND RELATED METHODS (ISRAEL) [CPA]
NBE 0026P	201827029863		RADER, PENG, BEERLI, WALDMEIER, GRAWUNDER	ROR1 ANTIBODY COMPOSITIONS AND RELATED METHODS (INDIA) [CPA]
NBE 0027P	2018-537754		RADER, PENG, BEERLI, WALDMEIER, GRAWUNDER	ROR1 ANTIBODY COMPOSITIONS AND RELATED METHODS (JAPAN) [CPA]

NBE 0028P	2018-7023595		RADER, PENG, BEERLI, WALDMEIER, GRAWUNDER	ROR1 ANTIBODY COMPOSITIONS AND RELATED METHODS (KOREA) [CPA]
NBE 0029P	2018/008926		RADER, PENG, BEERLI, WALDMEIER, GRAWUNDER	ROR1 ANTIBODY COMPOSITIONS AND RELATED METHODS (MEXICO) [CPA]
NBE 0030P	744571		RADER, PENG, BEERLI, WALDMEIER, GRAWUNDER	ROR1 ANTIBODY COMPOSITIONS AND RELATED METHODS (NEW ZEALAND) [CPA]
NBE 0004P	17/014311	WO 17/127664	RADER, PENG, BEERLI, WALDMEIER, GRAWUNDER	ROR1 ANTIBODY COMPOSITIONS AND RELATED METHODS (PCT)
NBE 0031P	1-2018-501554		RADER, PENG, BEERLI, WALDMEIER, GRAWUNDER	ROR1 ANTIBODY COMPOSITIONS AND RELATED METHODS (PHILIPPINES) [CPA]
NBE 0032P	2018129962		RADER, PENG, BEERLI, WALDMEIER, GRAWUNDER	ROR1 ANTIBODY COMPOSITIONS AND RELATED METHODS (RUSSIAN FEDERATION) [CPA]
NBE 0033P	11201806120W		RADER, PENG, BEERLI, WALDMEIER, GRAWUNDER	ROR1 ANTIBODY COMPOSITIONS AND RELATED METHODS (SINGAPORE) [CPA]
NBE 0034P	2018 08044		RADER, PENG, BEERLI, WALDMEIER, GRAWUNDER	ROR1 ANTIBODY COMPOSITIONS AND RELATED METHODS (UKRAINE) [CPA]
NBE 0036P	2018/04849		RADER, PENG, BEERLI, WALDMEIER, GRAWUNDER	ROR1 ANTIBODY COMPOSITIONS AND RELATED METHODS (SOUTH AFRICA) [CPA]
FLA 0187P	62/220,148		RADER, NANNA, ROUSH	DUAL VARIABLE DOMAIN IMMUNOCONJUGATES AND USES THEREOF (DISCL. NO. 15-35) (PROVISIONAL)
FLA 0232P	62/327,849		RADER, NANNA, ROUSH	DUAL VARIABLE DOMAIN IMMUNOCONJUGATES AND USES THEREOF (DISCL. NO. 15-35; MS 29327; 29449)
FLA 0313P	2,998,740		RADER, NANNA, ROUSH	DUAL VARIABLE DOMAIN IMMUNOCONJUGATES AND USES THEREOF (CANADA) [CPA-N]
FLA 0314P	201680054340.X		RADER, NANNA, ROUSH	DUAL VARIABLE DOMAIN IMMUNOCONJUGATES AND USES THEREOF (CHINA) [CPA-N]

FLA 0315P	16847428.6	3349795	RADER, NANNA, ROUSH	DUAL VARIABLE DOMAIN IMMUNOCONJUGATES AND USES THEREOF (EPO) [CPA-N]
FLA 0355P	19100878.6		RADER, NANNA, ROUSH	DUAL VARIABLE DOMAIN IMMUNOCONJUGATES AND USES THEREOF (HONG KONG)
FLA 0316P	2018-513765		RADER, NANNA, ROUSH	DUAL VARIABLE DOMAIN IMMUNOCONJUGATES AND USES THEREOF (JAPAN) [CPA-N]
FLA 0480P	2021-128507		RADER, NANNA, ROUSH	DUAL VARIABLE DOMAIN IMMUNOCONJUGATES AND USES THEREOF (JAPAN/DIV 1)
FLA 0237P	16/052214	WO 17/049139	RADER, NANNA, ROUSH	DUAL VARIABLE DOMAIN IMMUNOCONJUGATES AND USES THEREOF (PCT)
FLA 0317P	15/760,316		RADER, NANNA, ROUSH	DUAL VARIABLE DOMAIN IMMUNOCONJUGATES AND USES THEREOF (U.S. NATIONAL PHASE)
FLA 0207P	62/250,672		RIFFIN, KAMENECKA, CHANG, DOEBELIN	ROR GAMMA AGONISTS AS ENHANCERS OF PROTECTIVE IMMUNITY (DISCL. NO. 15-41) (PROVISIONAL)
FLA 0245P	16/059841	WO 17/079120	RIFFIN, KAMENECKA, CHANG, DOEBELIN	ROR GAMMA AGONISTS AS ENHANCERS OF PROTECTIVE IMMUNITY (PCT)
FLA 0330P	15/768,888		RIFFIN, KAMENECKA, CHANG, DOEBELIN	ROR GAMMA AGONISTS AS ENHANCERS OF PROTECTIVE IMMUNITY (U.S. NATIONAL PHASE)
FLA 0211P	62/240,689		ROUSH, DUCKETT, CLEVELAND, ROSENBERG	THERAPEUTIC TARGETING OF CASEIN KINASE 1 DELTA IN BREAST CANCER (DISCL. NO. 15-50; MS 29228) (PROVISIONAL)
FLA 0327P	2016338639		ROUSH, DUCKETT, CLEVELAND, ROSENBERG	THERAPEUTIC TARGETING OF CASEIN KINASE 1 DELTA IN BREAST CANCER (AUSTRALIA)
FLA 0323P	3,001,903		ROUSH, DUCKETT, CLEVELAND, ROSENBERG	THERAPEUTIC TARGETING OF CASEIN KINASE 1 DELTA IN BREAST CANCER (CANADA)
FLA 0328P	201680071705.X		ROUSH, DUCKETT,	THERAPEUTIC TARGETING OF CASEIN

			CLEVELAND, ROSENBERG	KINASE 1 DELTA IN BREAST CANCER (CHINA) THERAPEUTIC
FLA 0392P	16/694,380		ROUSH, DUCKETT, CLEVELAND, ROSENBERG	TARGETING OF CASEIN KINASE 1 DELTA IN BREAST CANCER (U.S. NATIONAL PHASE) THERAPEUTIC
FLA 0324P	16855974.8		ROUSH, DUCKETT, CLEVELAND, ROSENBERG	TARGETING OF CASEIN KINASE 1 DELTA IN BREAST CANCER (EPO) THERAPEUTIC
FLA 0356P	19101778.5		ROUSH, DUCKETT, CLEVELAND, ROSENBERG	TARGETING OF CASEIN KINASE 1 DELTA IN BREAST CANCER (HONG KONG) THERAPEUTIC
FLA 0325P	2018-519027		ROUSH, DUCKETT, CLEVELAND, ROSENBERG	TARGETING OF CASEIN KINASE 1 DELTA IN BREAST CANCER (JAPAN) THERAPEUTIC
FLA 0242P	16/055436	WO 17/066055	ROUSH, DUCKETT, CLEVELAND, ROSENBERG	TARGETING OF CASEIN KINASE 1 DELTA IN BREAST CANCER (PCT) THERAPEUTIC
FLA 0326P	15/768,257	10,603,322	ROUSH, DUCKETT, CLEVELAND, ROSENBERG	TARGETING OF CASEIN KINASE 1 DELTA IN BREAST CANCER (U.S. NATIONAL PHASE) [CPA- N] CD4 MUTEINS AND METHODS OF USING THE SAME (DISCL. NO. 16-43; MS 29670) (PROVISIONAL)
EMM 0004P	62/645,903		FARZAN, GARDNER, FETZER	CD4 MUTEINS AND METHODS OF USING THE SAME (ARIPO) [CPA]
EMM 0011P	2020/012733		FARZAN, GARDNER, FETZER, ALPERT, BAILEY	CD4 MUTEINS AND METHODS OF USING THE SAME (AUSTRALIA) [CPA]
EMM 0012P	2019240319		FARZAN, GARDNER, FETZER, ALPERT, BAILEY	CD4 MUTEINS AND METHODS OF USING THE SAME (BRAZIL) [CPA]
EMM 0013P	112020019107-8		FARZAN, GARDNER, FETZER, ALPERT, BAILEY	CD4 MUTEINS AND METHODS OF USING THE SAME (CANADA) [CPA]
EMM 0014P	3,094,691		FARZAN, GARDNER, FETZER, ALPERT, BAILEY	CD4 MUTEINS AND METHODS OF USING THE SAME (CHINA) [CPA]
EMM 0015P	201980031890.3		FARZAN, GARDNER, FETZER, ALPERT, BAILEY	CD4 MUTEINS AND METHODS OF USING THE SAME (CHINA) [CPA]

EMM 0016P	202092229		FARZAN, GARDNER, FETZER, ALPERT, BAILEY	CD4 MUTEINS AND METHODS OF USING THE SAME (EURASIA) [CPA]
EMM 0017P	19771245.8		FARZAN, GARDNER, FETZER, ALPERT, BAILEY	CD4 MUTEINS AND METHODS OF USING THE SAME (EPO) [CPA]
EMM 0018P	277458		FARZAN, GARDNER, FETZER, ALPERT, BAILEY	CD4 MUTEINS AND METHODS OF USING THE SAME (ISRAEL) [CPA]
EMM 0019P	202047045927		FARZAN, GARDNER, FETZER, ALPERT, BAILEY	CD4 MUTEINS AND METHODS OF USING THE SAME (INDIA) [CPA]
EMM 0020P	2021-500499		FARZAN, GARDNER, FETZER, ALPERT, BAILEY	CD4 MUTEINS AND METHODS OF USING THE SAME (JAPAN) [CPA]
EMM 0021P	2020-7030006		FARZAN, GARDNER, FETZER, ALPERT, BAILEY	CD4 MUTEINS AND METHODS OF USING THE SAME (KOREA) [CPA]
EMM 0022P	2020/009817		FARZAN, GARDNER, FETZER, ALPERT, BAILEY	CD4 MUTEINS AND METHODS OF USING THE SAME (MEXICO) [CPA]
EMM 0023P	769146		FARZAN, GARDNER, FETZER, ALPERT, BAILEY	CD4 MUTEINS AND METHODS OF USING THE SAME (NEW ZEALAND) [CPA]
EMM 0006P	19/023422	WO 19/183387	FARZAN, GARDNER, FETZER, ALPERT, BAILEY	CD4 MUTEINS AND METHODS OF USING THE SAME (PCT)
EMM 0024P	11202009194X		FARZAN, GARDNER, FETZER, ALPERT, BAILEY	CD4 MUTEINS AND METHODS OF USING THE SAME (SINGAPORE) [CPA]
EMM 0025P	16/982,134		FARZAN, GARDNER, FETZER, ALPERT, BAILEY	CD4 MUTEINS AND METHODS OF USING THE SAME (U.S. NATIONAL PHASE)
EMM 0026P	2020/06480		FARZAN, GARDNER, FETZER, ALPERT, BAILEY	CD4 MUTEINS AND METHODS OF USING THE SAME (SOUTH AFRICA) [CPA]
FLA 0253P	62/460,201		DISNEY	SMALL MOLECULE INHIBITION OF MICRO- RNA-210 REPROGRAMS AN ONCOGENIC HYPOXIC CIRCUIT (DISCL. NO. 17-07; MS 29469) (PROVISIONAL)

ETI 0066P	18/018512	WO 18/152414	DISNEY	SMALL MOLECULE INHIBITION OF MICRO- RNA-210 REPROGRAMS AN ONCOGENIC HYPOXIC CIRCUIT (PCT) (A-2)
ETI 0056P	16/486,211		DISNEY	SMALL MOLECULE INHIBITION OF MICRO- RNA-210 REPROGRAMS AN ONCOGENIC HYPOXIC CIRCUIT (DISCL. NO. 17-07) (U.S. NATIONAL PHASE)
FLA 0254P	62/460,184		DISNEY, VELAGAPUDI	DEFINING RNA-SMALL MOLECULE AFFINITY LANDSCAPES ENABLES DESIGN OF A SMALL MOLECULAR INHIBITOR OF AN ONCOGENIC NON- CODING RNA (DISCL. NO. 17-08; MS 29471) (PROVISIONAL)
ETI 0067P	18/000020	WO 18/151810	DISNEY, VELAGAPUDI	DEFINING RNA-SMALL MOLECULE AFFINITY LANDSCAPES ENABLES DESIGN OF A SMALL MOLECULE INHIBITOR OF AN ONCOGENIC NON- CODING RNA (PCT) (A-2)
ETI 0057P	16/486,223		DISNEY, VELAGAPUDI KAMENECKA, GRIFFIN, LIN, PUIGSERVER, SHARABI, SCHREIBER, SCHILLING, NAG, BITTKER	DEFINING RNA-SMALL MOLECULE AFFINITY LANDSCAPES ENABLES DESIGN OF A SMALL MOLECULE INHIBITOR OF AN ONCOGENIC NON- CODING RNA (DISCL. NO. 17-08; MS 29471) (U.S. NATIONAL PHASE)
FLA 0255P	62/474,861		PUIGSERVER, SHARABI, KAMENECKA, GRIFFIN, SCHREIBER, SCHILLING, NAG, BITTKER	SELECTIVE INHIBITION OF GLUCONEOGENIC ACTIVITY (DISCL. NO. 17- 09; MS 29470) (PROVISIONAL)
FLA 0393P	18772113.9		PUIGSERVER, SHARABI, KAMENECKA, GRIFFIN, SCHREIBER, SCHILLING, NAG, BITTKER	SELECTIVE INHIBITION OF GLUCONEOGENIC ACTIVITY (EPO)
FLA 0312P	18/023497	WO 18/175537	SCHREIBER,	SELECTIVE INHIBITION OF GLUCONEOGENIC ACTIVITY (PCT)

			SCHILLING, NAG, BITTKER	
			PUIGSERVER, SHARABI, KAMENECKA, GRIFFIN, SCHREIBER, SCHILLING, NAG, BITTKER	SELECTIVE INHIBITION OF GLUCONEOGENIC ACTIVITY (U.S. NATIONAL PHASE) OXIDIZING LIQUID MEDIA FOR CHEMICAL TRANSFORMATIONS (PROVISIONAL) (DISCL. NO. 17-15)
FLA 0376P	16/496,178			
			PERIANA, HASHIGUCHI, KONNICK	
FLA 0271P	62/511,173			
			PERIANA, HASHIGUCHI, KONNICK	OXIDATION OF ALKANE TO ALKENE (PROVISIONAL) DIRECT OXIDATION OF OLEFINS TO OXYGENATED SPECIES (PROVISIONAL) OXIDIZING LIQUID MEDIA FOR CHEMICAL TRANSFORMATIONS (AUSTRALIA)
FLA 0339P	62/654,119			
			PERIANA, HASHIGUCHI, KONNICK	OXIDIZING LIQUID MEDIA FOR CHEMICAL TRANSFORMATIONS (BRAZIL)
FLA 0340P	62/654,133			
			PERIANA, HASHIGUCHI, KONNICK	OXIDIZING LIQUID MEDIA FOR CHEMICAL TRANSFORMATIONS (CANADA)
FLA 0399P	2018272055	2018272055		
			PERIANA, HASHIGUCHI, KONNICK	OXIDIZING LIQUID MEDIA FOR CHEMICAL TRANSFORMATIONS (CHINA)
FLA 0383P	112019024660.6			
			PERIANA, HASHIGUCHI, KONNICK	OXIDIZING LIQUID MEDIA FOR CHEMICAL TRANSFORMATIONS (INDONESIA)
FLA 0400P	3,064,326			
			PERIANA, HASHIGUCHI, KONNICK	OXIDIZING LIQUID MEDIA FOR CHEMICAL TRANSFORMATIONS (INDIA)
FLA 0384P	2018800343614			
			PERIANA, HASHIGUCHI, KONNICK	OXIDIZING LIQUID MEDIA FOR CHEMICAL TRANSFORMATIONS (EPO) OXIDIZING LIQUID MEDIA FOR CHEMICAL TRANSFORMATIONS (INDONESIA)
FLA 0401P	18733730.8			
			PERIANA, HASHIGUCHI, KONNICK	OXIDIZING LIQUID MEDIA FOR CHEMICAL TRANSFORMATIONS (INDONESIA)
FLA 0402P	P00201912118			
			PERIANA, HASHIGUCHI, KONNICK	OXIDIZING LIQUID MEDIA FOR CHEMICAL TRANSFORMATIONS (INDIA)
FLA 0403P	201917052412			
			PERIANA, HASHIGUCHI, KONNICK	OXIDIZING LIQUID MEDIA FOR CHEMICAL TRANSFORMATIONS (PCT) (SEE 1949 & 1950)
FLA 0341P	18/034698	WO 18/218171		

FLA 0385P	201911/000626		PERIANA, HASHIGUCHI, KONNICK	OXIDIZING LIQUID MEDIA FOR CHEMICAL TRANSFORMATIONS (QATAR)
FLA 0404P	2019143400	2733385	PERIANA, HASHIGUCHI, KONNICK	OXIDIZING LIQUID MEDIA FOR CHEMICAL TRANSFORMATIONS (RUSSIAN FEDERATION)
FLA 0375P	16/616,604		PERIANA, HASHIGUCHI, KONNICK	OXIDIZING LIQUID MEDIA FOR CHEMICAL TRANSFORMATIONS (U.S. NATIONAL PHASE)
TSR 2148P	62/084,932		AUBE, FRANKOWSKI, PRISINZANO, BOHN	ANTAGONISTS OF THE KAPPA OPIOID RECEPTOR (PROVISIONAL)
TSR 2284P	16/179,637	10,829,453	AUBE, FRANKOWSKI, PRISINZANO, BOHN	ANTAGONISTS OF THE KAPPA OPIOID RECEPTOR (CON 1) (DISCL. NO. 20-34)
TSR 2149P	15/062708	WO 16/086149	AUBE, FRANKOWSKI, PRISINZANO, BOHN	ANTAGONISTS OF THE KAPPA OPIOID RECEPTOR (PCT)
TSR 2150P	15/529,290	10,118,896	AUBE, FRANKOWSKI, PRISINZANO, BOHN	ANTAGONISTS OF THE KAPPA OPIOID RECEPTOR (U.S. NATIONAL PHASE)
ETI 0032P	62/587,606		DISNEY, BLIZZARD, RZUCZEK, NDUNGU	BIS-BENZIMIDAZOLE COMPOUNDS AND METHODS OF USING THE SAME (DISCL. NO. 17-63, 17-64, 17-65) (PROVISIONAL)
ETI 0073P	18816369.5		DISNEY, BLIZZARD, RZUCZEK, NDUNGU, VACCA, JENNINGS, PUSHECHNIKOV	BIS-BENZIMIDAZOLE COMPOUNDS AND METHODS OF USING THE SAME (EPO)
ETI 0043P	18/061442	WO 19/099777	DISNEY, BLIZZARD, RZUCZEK, NDUNGU, VACCA, JENNINGS, PUSHECHNIKOV	BIS-BENZIMIDAZOLE COMPOUNDS AND METHODS OF USING THE SAME (PCT)
ETI 0044P	107140891		DISNEY, BLIZZARD, RZUCZEK, NDUNGU	BIS-BENZIMIDAZOLE COMPOUNDS AND METHODS OF USING THE SAME (TAIWAN)
ETI 0045P	16/193,486	10,961,202	DISNEY, BLIZZARD, RZUCZEK,	BIS-BENZIMIDAZOLE COMPOUNDS AND METHODS OF USING THE

			NDUNGU, VACCA, JENNINGS, PUSHECHNIKOV	SAME (U.S. NATIONAL PHASE) (A-1)
FLA 0301P	62/593,395		NIEDERNHOFER	METHODS FOR DETERMINING BIOLOGICAL AGE (DISCL. NO. 16-64; MS 29609) (PROVISIONAL) METHODS AND MATERIALS FOR ASSESSING BIOLOGICAL AGE AND SLOWING THE PROGRESS OF EXCESSIVE BIOLOGICAL AGING (PCT) METHODS AND MATERIALS FOR ASSESSING BIOLOGICAL AGE AND SLOWING THE PROGRESS OF EXCESSIVE BIOLOGICAL AGING (U.S. NATIONAL PHASE)
TSR 2328P	18/063485	WO 19/109044	NIEDERNHOFER, YOUSEFZADEH	DIRECT OXIDATIVE AMINATION OF HYDROCARBONS (PROVISIONAL) (DISCL. NO. 17-70) DIRECT OXIDATIVE AMINATION OF HYDROCARBONS (AUSTRALIA) DIRECT OXIDATIVE AMINATION OF HYDROCARBONS (BRAZIL) DIRECT OXIDATIVE AMINATION OF HYDROCARBONS (CANADA)
TSR 2465P	16/768,615		NIEDERNHOFER, YOUSEFZADEH	DIRECT OXIDATIVE AMINATION OF HYDROCARBONS (CHINA)
FLA 0302P	62/593,320		PERIANA, HASHIGUCHI, PARK, GUNSALUS	DIRECT OXIDATIVE AMINATION OF HYDROCARBONS (INDONESIA)
FLA 0433P	2018375831		PERIANA, HASHIGUCHI, PARK, GUNSALUS	DIRECT OXIDATIVE AMINATION OF HYDROCARBONS (INDIA)
FLA 0428P	112020010915-0		PERIANA, HASHIGUCHI, PARK, GUNSALUS	
FLA 0429P	3,083,593		PERIANA, HASHIGUCHI, PARK, GUNSALUS	
FLA 0438P	2018800883203		PERIANA, HASHIGUCHI, PARK, GUNSALUS	
FLA 0434P	18830555.1		PERIANA, HASHIGUCHI, PARK, GUNSALUS	
FLA 0439P	P00202004496		PERIANA, HASHIGUCHI, PARK, GUNSALUS	
FLA 0437P	202017027086		PERIANA, HASHIGUCHI, PARK, GUNSALUS	

FLA 0354P	18/063489	WO 19/109045	PERIANA, HASHIGUCHI, PARK, GUNSALUS PERIANA, HASHIGUCHI, PARK, GUNSALUS	DIRECT OXIDATIVE AMINATION OF HYDROCARBONS (PCT) DIRECT OXIDATIVE AMINATION OF HYDROCARBONS (QATARI) DIRECT OXIDATIVE AMINATION OF HYDROCARBONS (RUSSIAN FEDERATION) DIRECT OXIDATIVE AMINATION OF HYDROCARBONS (U.S. NATIONAL PHASE)
FLA 0426P	202005/000286		GUNSALUS PERIANA, HASHIGUCHI, PARK, GUNSALUS	SMALL MOLECULE INHIBITORS OF CDK12/CDK13 (DISCL. NO. 17-20) (PROVISIONAL)
FLA 0448P	2020121686		PERIANA, HASHIGUCHI, PARK, GUNSALUS	SMALL MOLECULE INHIBITORS OF CDK12/CDK13 (PCT)
FLA 0425P	16/767,831		PERIANA, HASHIGUCHI, PARK, GUNSALUS	SMALL MOLECULE INHIBITORS OF CDK12/CDK13 (U.S. NATIONAL PHASE)
FLA 0310P	62/668,628		ROUSH, DUCKETT, MONASTYRSKYI	METHODS RELATED TO PARKINSON'S DISEASE AND SYNUCLEINOPATHIES (DISCL. NO. 18-02; MS 29639) (PROVISIONAL)
FLA 0367P	19/031116	WO 19/217421	ROUSH, DUCKETT, MONASTYRSKYI	METHODS RELATED TO PARKINSON'S DISEASE AND SYNUCLEINOPATHIES (PCT)
FLA 0458P	17/053,652		ROUSH, DUCKETT, MONASTYRSKYI	METHODS RELATED TO PARKINSON'S DISEASE AND SYNUCLEINOPATHIES (U.S. NATIONAL PHASE)
FLA 0311P	62/629,503		GRASSI, LASMÉZAS, M. ZHOU	METHODS RELATED TO PARKINSON'S DISEASE AND SYNUCLEINOPATHIES (U.S. NATIONAL PHASE)
VIT 0001P	19/017718	WO 19/157527	GRASSI, LASMÉZAS, M. ZHOU	METHODS RELATED TO PARKINSON'S DISEASE AND SYNUCLEINOPATHIES (PCT)
VIT 0004P	16/969,020		GRASSI, LASMÉZAS, M. ZHOU	METHODS RELATED TO PARKINSON'S DISEASE AND SYNUCLEINOPATHIES (U.S. NATIONAL PHASE)
FLA 0332P	62/685,158		MILLER, GRIFFIN, KAMENECKA, RUMBAUGH, SURMAN, YOUNG, DUDDY, RADNAI	NONMUSCLE MYOSIN II INHIBITORS FOR SUBSTANCE USE RELAPSE (DISCL. NO. 17-45) (PROVISIONAL)
FLA 0441P	2019285034		MILLER, GRIFFIN, KAMENECKA, RUMBAUGH, SURMAN,	NONMUSCLE MYOSIN II INHIBITORS FOR SUBSTANCE USE RELAPSE (AUSTRALIA)

			YOUNG, DUDDY, RADNAI	
FLA 0442P	3,103,144		MILLER, GRIFFIN, KAMENECKA, RUMBAUGH, SURMAN, YOUNG, DUDDY, RADNAI	NONMUSCLE MYOSIN II INHIBITORS FOR SUBSTANCE USE RELAPSE (CANADA) [CPA-N]
FLA 0443P	201980039813.2		MILLER, GRIFFIN, KAMENECKA, RUMBAUGH, SURMAN, YOUNG, DUDDY, RADNAI	NONMUSCLE MYOSIN II INHIBITORS FOR SUBSTANCE USE RELAPSE (CHINA)
FLA 0444P	19819613.1		MILLER, GRIFFIN, KAMENECKA, RUMBAUGH, SURMAN, YOUNG, DUDDY, RADNAI	NONMUSCLE MYOSIN II INHIBITORS FOR SUBSTANCE USE RELAPSE (EPO)
FLA 0482P	62021040341.1		MILLER, GRIFFIN, KAMENECKA, RUMBAUGH, SURMAN, YOUNG, DUDDY, RADNAI	NONMUSCLE MYOSIN II INHIBITORS FOR SUBSTANCE USE RELAPSE (HONG KONG/EPO)
FLA 0445P	2020-568988		MILLER, GRIFFIN, KAMENECKA, RUMBAUGH, SURMAN, YOUNG, DUDDY, RADNAI	NONMUSCLE MYOSIN II INHIBITORS FOR SUBSTANCE USE RELAPSE (JAPAN)
FLA 0446P	2021-7000761		MILLER, GRIFFIN, KAMENECKA, RUMBAUGH, SURMAN, YOUNG, DUDDY, RADNAI	NONMUSCLE MYOSIN II INHIBITORS FOR SUBSTANCE USE RELAPSE (KOREA)
FLA 0366P	19/036897	WO 19/241469	MILLER, GRIFFIN, KAMENECKA, RUMBAUGH, SURMAN, YOUNG, DUDDY, RADNAI	NONMUSCLE MYOSIN II INHIBITORS FOR SUBSTANCE USE RELAPSE (PCT)
FLA 0447P	17/250,203		MILLER, GRIFFIN, KAMENECKA, RUMBAUGH,	NONMUSCLE MYOSIN II INHIBITORS FOR SUBSTANCE USE RELAPSE (U.S. NATIONAL PHASE)

			SURMAN, YOUNG, DUDDY, RADNAI	
FLA 0318P	63/092,684		NETTLES, BRUNO, KAMENECKA, MICALIZIO	THERAPEUTIC USES OF GLUCOCORTICOIDS WITH ANABOLIC EFFECTS IN SKELETAL MUSCLE (DISCL. NO. 18-04; MS 29669) (PROVISIONAL)
FLA 0487P	21/054804		NETTLES, BRUNO, KAMENECKA, MICALIZIO	THERAPEUTIC USES OF GLUCOCORTICOIDS WITH ANABOLIC EFFECTS IN SKELETAL MUSCLE (PCT)
FLA 0320P	62/744,339		RADER, HWANG, NILCHAN	ANTIBODY COMPOUNDS WITH REACTIVE ARGININE AND RELATED ANTIBODY DRUG CONJUGATES (DISCL. NO. 18-08; MS 29771) (PROVISIONAL)
FLA 0470P	201980081369.0		RADER, HWANG, NILCHAN	ANTIBODY COMPOUNDS WITH REACTIVE ARGININE AND RELATED ANTIBODY DRUG CONJUGATES (CHINA) [CPA-N]
FLA 0471P	19871937.9		RADER, HWANG, NILCHAN	ANTIBODY COMPOUNDS WITH REACTIVE ARGININE AND RELATED ANTIBODY DRUG CONJUGATES (EPO) [CPA- N]
FLA 0377P	19/055224	WO 20/076849	RADER, HWANG, NILCHAN	ANTIBODY COMPOUNDS WITH REACTIVE ARGININE AND RELATED ANTIBODY DRUG CONJUGATES (PCT)
FLA 0472P	17/284,192		RADER, HWANG, NILCHAN	ANTIBODY COMPOUNDS WITH REACTIVE ARGININE AND RELATED ANTIBODY DRUG CONJUGATES (U.S. NATIONAL PHASE)
FLA 0321P			RADER, HWANG	SITE-SPECIFIC CYSTEINE CONJUGATION TO AN ENGINEERED MUTANT OF MONOCLONAL ANTIBODY H38C2 (DISCL. NO. 18-09) (PROVISIONAL)
ETI 0042P	62/661,776		DISNEY	SMALL MOLECULE TARGETED RECRUITMENT OF A NUCLEASE TO RNA (DISCL. NO. 18-18; MS 29673) (PROVISIONAL) (A- 1, A-2)

ETI 0075P	19791801.4		DISNEY	SMALL MOLECULE TARGETED RECRUITMENT OF A NUCLEASE TO RNA (EPO) [CPA]
ETI 0083P	62021037901.7		DISNEY	SMALL MOLECULE TARGETED RECRUITMENT OF A NUCLEASE TO RNA (HONG KONG/EPO)
ETI 0076P	2020-559531		DISNEY	SMALL MOLECULE TARGETED RECRUITMENT OF A NUCLEASE TO RNA (JAPAN)
ETI 0051P	19/028955	WO 19/209975	DISNEY	SMALL MOLECULE TARGETED RECRUITMENT OF A NUCLEASE TO RNA (PCT)
ETI 0077P	17/050,219		DISNEY	SMALL MOLECULE TARGETED RECRUITMENT OF A NUCLEASE TO RNA (U.S. NATIONAL PHASE)
FLA 0331P	62/657,581		CLURMAN, ZHENG, SPICER, SCAMPAVIA, BANNISTER, HANDELI	UBIQUITIN LIGASE AGONISTS, PHARMACEUTICAL COMPOSITIONS, AND RELATED METHODS OF USE (DISCL. NO. 18-23) (PROVISIONAL)
FLA 0459P	19784562.1	3774766	CLURMAN, ZHENG, SPICER, SCAMPAVIA, BANNISTER, HANDELI	E3 UBIQUITIN LIGASE AGONISTS, PHARMACEUTICAL COMPOSITIONS INCLUDING THE E3 UBIQUITIN LIGASE AGONISTS, RELATED METHODS OF USE (EPO)
FLA 0364P	19/027309	WO 19/200310	CLURMAN, ZHENG, SPICER, SCAMPAVIA, BANNISTER, HANDELI	E3 UBIQUITIN LIGASE AGONISTS, PHARMACEUTICAL COMPOSITIONS INCLUDING THE E3 UBIQUITIN LIGASE AGONISTS, RELATED METHODS OF USE (PCT)
FLA 0460P	17/046,973		CLURMAN, ZHENG, SPICER, SCAMPAVIA, BANNISTER, HANDELI	E3 UBIQUITIN LIGASE AGONISTS, PHARMACEUTICAL COMPOSITIONS INCLUDING THE E3 UBIQUITIN LIGASE AGONISTS, RELATED METHODS OF USE (U.S. NATIONAL PHASE)
FLA 0334P	62/746,343		MARTEMYANOV , GRILL	METHODS RELATED TO OPIOID THERAPEUTICS

FLA 0476P	3,121,108		MARTEMYANOV , GRILL	(DISCL. NO. 18-24; MS 29686) (PROVISIONAL) METHODS RELATED TO OPIOID THERAPEUTICS (CANADA) [CPA-N] METHODS RELATED TO
FLA 0378P	19/056284	WO 20/081538	MARTEMYANOV , GRILL	OPIOID THERAPEUTICS (PCT) METHODS RELATED TO
FLA 0473P	17/286,187		MARTEMYANOV , GRILL	OPIOID THERAPEUTICS (U.S. NATIONAL PHASE) PROFILING RNA-SMALL MOLECULE BINDING SITES WITH
FLA 0345P	62/729,516		DISNEY	OLIGONUCLEOTIDES (DISCL. NO. 18-57; MS 29750) (PROVISIONAL) PROFILING RNA-SMALL MOLECULE BINDING SITES WITH
ETI 0060P	19/050531	WO 20/055953	DISNEY	OLIGONUCLEOTIDES (PCT) (A-2) PROFILING RNA-SMALL MOLECULE BINDING SITES WITH
ETI 0079P	17/275,537		DISNEY	OLIGONUCLEOTIDES (U.S. NATIONAL PHASE) (A-2) TARGET VALIDATION AND PROFILING OF THE RNA TARGETS OF SMALL MOLECULES (DISCL. NO. 18-62; MS 29747)
FLA 0348P	62/743,996		DISNEY	(PROVISIONAL) TARGET VALIDATION AND PROFILING OF THE RNA TARGETS OF SMALL MOLECULES (PCT) (A-2)
ETI 0058P	19/053179	WO 20/076511	DISNEY	TARGET VALIDATION AND PROFILING OF THE RNA TARGETS OF SMALL MOLECULES (U.S. NATIONAL PHASE) (A-2)
ETI 0080P	17/284,297		DISNEY	A CROSS-LINKING APPROACH TO MAP SMALL MOLECULE-RNA BINDING SITES IN CELLS (DISCL. NO. 18-63; MS 29757)
ETI 0068P	62/804,308		DISNEY	(PROVISIONAL) (A-2) A CROSS-LINKING APPROACH TO MAP SMALL MOLECULE-RNA BINDING SITES IN CELLS (PCT)
ETI 0059P	20/017725	WO 20/167811	DISNEY	A CROSS-LINKING APPROACH TO MAP
ETI 0081P	17/419,654		DISNEY	

ETI 0063P	62/771,798		DISNEY, CHILDS- DISNEY, FUERST	SMALL MOLECULE-RNA BINDING SITES IN CELLS (U.S. NATIONAL PHASE) SMALL MOLECULES THAT TARGET THE RNA THAT CAUSES ALS (DISCL. NO. 18-58; MS 29748) (PROVISIONAL) (A-1) SMALL MOLECULES THAT TARGET THE RNA THAT CAUSES ALS (DISCL. NO. 18-58; MS 29748) (PROVISIONAL)
ETI 0064P	62/887,127		DISNEY, CHILDS- DISNEY, FUERST	SMALL MOLECULES THAT TARGET THE RNA THAT CAUSES ALS (PCT) SMALL MOLECULES THAT TARGET THE RNA THAT CAUSES ALS (DISCL. NO. 20-40) (PROVISIONAL) SMALL MOLECULES THAT TARGET THE RNA THAT CAUSES ALS (PCT)
ETI 0069P	19/063757		DISNEY, CHILDS- DISNEY, FUERST	ANTIBODIES TARGETING CELL SURFACE
ETI 0074P	63/075,390		DISNEY, BLIZZARD, USIU	DEPOSITED COMPLEMENT PROTEIN C3d AND USE THEREOF (DISCL. NO. 18- 83) (PROVISIONAL)
ETI 0078P	21/049357		DISNEY, BLIZZARD, USIU	ANTIBODIES TARGETING CELL SURFACE
TSR 2288P	62/945,569		WIESTNER, RADER, PENG, BASKAR, GAGLIONE	DEPOSITED COMPLEMENT PROTEIN C3d AND USE THEREOF (PCT)
TSR 2482P	20/063809	WO 21/119012	WIESTNER, RADER, PENG, BASKAR, GAGLIONE	ANTIBODIES TARGETING CELL SURFACE
FLA 0405P	2018273972	2018273972	PERIANA, HASHIGUCHI, KONNICK	DEPOSITED COMPLEMENT PROTEIN C3d AND USE THEREOF (PCT)
FLA 0386P	112019024652.5		PERIANA, HASHIGUCHI, KONNICK	OXIDATION OF ALKANE TO ALKENE (AUSTRALIA)
FLA 0406P	3,064,335		PERIANA, HASHIGUCHI, KONNICK	OXIDATION OF ALKANE TO ALKENE (BRAZIL)
FLA 0387P	2018800343296		PERIANA, HASHIGUCHI, KONNICK	OXIDATION OF ALKANE TO ALKENE (CANADA)
FLA 0407P	18731316.8		PERIANA, HASHIGUCHI, KONNICK	OXIDATION OF ALKANE TO ALKENE (CHINA)
FLA 0408P	P00201912116		PERIANA, HASHIGUCHI, KONNICK	OXIDATION OF ALKANE TO ALKENE (EPO)
			PERIANA, HASHIGUCHI, KONNICK	OXIDATION OF ALKANE TO ALKENE (INDONESIA)

FLA 0409P	201917052413		PERIANA, HASHIGUCHI, KONNICK	OXIDATION OF ALKANE TO ALKENE (INDIA)
FLA 0342P	18/034706	WO 18/218176	PERIANA, HASHIGUCHI, KONNICK	OXIDATION OF ALKANE TO ALKENE (PCT) (DISCL. NO. 18-85) (CLAIMS PRIORITY TO 1798)
FLA 0388P	201911/000628		PERIANA, HASHIGUCHI, KONNICK	OXIDATION OF ALKANE TO ALKENE (QATAR)
FLA 0410P	2019143406	2733408	PERIANA, HASHIGUCHI, KONNICK	OXIDATION OF ALKANE TO ALKENE (RUSSIAN FEDERATION)
FLA 0411P	16/616,615	11,078,136	PERIANA, HASHIGUCHI, KONNICK	OXIDATION OF ALKANE TO ALKENE (U.S. NATIONAL PHASE)
FLA 0412P	2018272065	2018272065	PERIANA, HASHIGUCHI, KONNICK	DIRECT OXIDATION OF OLEFINS TO OXYGENATED SPECIES (AUSTRALIA)
FLA 0389P	112019024644-4		PERIANA, HASHIGUCHI, KONNICK	DIRECT OXIDATION OF OLEFINS TO OXYGENATED SPECIES (BRAZIL)
FLA 0413P	3,064,336		PERIANA, HASHIGUCHI, KONNICK	DIRECT OXIDATION OF OLEFINS TO OXYGENATED SPECIES (CANADA)
FLA 0390P	201880034360X		PERIANA, HASHIGUCHI, KONNICK	DIRECT OXIDATION OF OLEFINS TO OXYGENATED SPECIES (CHINA)
FLA 0414P	18733731.6		PERIANA, HASHIGUCHI, KONNICK	DIRECT OXIDATION OF OLEFINS TO OXYGENATED SPECIES (EPO)
FLA 0415P	P00201912122		PERIANA, HASHIGUCHI, KONNICK	DIRECT OXIDATION OF OLEFINS TO OXYGENATED SPECIES (INDONESIA)
FLA 0416P	201917052414		PERIANA, HASHIGUCHI, KONNICK	DIRECT OXIDATION OF OLEFINS TO OXYGENATED SPECIES (INDIA)
FLA 0343P	18/034717	WO 18/218186	PERIANA, HASHIGUCHI, KONNICK	DIRECT OXIDATION OF OLEFINS TO OXYGENATED SPECIES (PCT) (DISCL. NO. 18-86) (CLAIMS PRIORITY TO 1798)
FLA 0391P	201911/000629		PERIANA, HASHIGUCHI, KONNICK	DIRECT OXIDATION OF OLEFINS TO OXYGENATED SPECIES (QATAR)

FLA 0417P	2019143401	2732752	PERIANA, HASHIGUCHI, KONNICK	DIRECT OXIDATION OF OLEFINS TO OXYGENATED SPECIES (RUSSIAN FEDERATION) DIRECT OXIDATION OF OLEFINS TO OXYGENATED SPECIES (U.S. NATIONAL PHASE)
FLA 0418P	16/616,626	10,858,301	PERIANA, HASHIGUCHI, KONNICK	CHEMICAL UNCOUPLERS OF RESPIRATION AND METHODS OF USE THEREOF (DISCL. NO. 19- 04) (PROVISIONAL)
FLA 0357P	62/592,611		SPIEGELMAN, LONG	CHEMICAL UNCOUPLERS OF RESPIRATION AND METHODS OF USE THEREOF (PCT)
FLA 0358P	18/062974	19/108739	SPIEGELMAN, LONG, LIN, KAMENECKA, GRIFFIN	CHEMICAL UNCOUPLERS OF RESPIRATION AND METHODS OF USE THEREOF (U.S. NATIONAL PHASE)
FLA 0422P	16/768,211		SPIEGELMAN, LONG, LIN, KAMENECKA, GRIFFIN	TARGET VALIDATION, BINDING SITE IDENTIFICATION, AND PROFILING OF RNA TARGETS (DISCL. NO. 19- 02) (PROVISIONAL)
FLA 0360P	62/867,582		DISNEY	TARGET VALIDATION, BINDING SITE IDENTIFICATION, AND PROFILING OF RNA TARGETS (PCT)
FLA 0431P	20/070175	WO 20/264560	DISNEY	FRAGMENT-BASED SCREENING TO IDENTIFY SMALL MOLECULES THAT SELECTIVELY BIND RNA (DISCL. NO. 19-03) (PROVISIONAL)
FLA 0361P	62/867,607		DISNEY	FRAGMENT-BASED SCREENING TO IDENTIFY SMALL MOLECULES THAT SELECTIVELY BIND RNA (PCT) (MS 30000)
FLA 0435P	20/070189	WO 20/264572	DISNEY	MODULATOR OF TREM-1 SIGNALING FOR USE IN THERAPY (MS 29822) (PROVISIONAL)
FLA 0362P	62/828,805		GRIFFIN, M.R. CHANG	MODULATOR OF TREM-1 SIGNALING FOR USE IN THERAPY (MS 29822) (PROVISIONAL)
SNK 0008P	62/828,978		GRIFFIN, M.R. CHANG, FISHERMAN, SUZMAN	
SNK 0012P	2020253486		GRIFFIN, M.R. CHANG,	METHOD OF INHIBITING TREM-1 (AUSTRALIA)

			FISHERMAN, SUZMAN	
SNK 0013P	3,132,179		GRIFFIN, M.R. CHANG, FISHERMAN, SUZMAN	METHOD OF INHIBITING TREM-1 (CANADA)
SNK 0014P	20784271.7		GRIFFIN, M.R. CHANG, FISHERMAN, SUZMAN	METHOD OF INHIBITING TREM-1 (EPO)
SNK 0007P	20/026526	WO 20/206213	GRIFFIN, M.R. CHANG, FISHERMAN, SUZMAN	METHOD OF INHIBITING TREM-1 (PCT) SMALL MOLECULES FOR CANCER THERAPY THAT REDUCE THE EXPRESSION OF TRANSCRIPTION FACTORS KLF5 AND EGR-1 (DISCL. NO. 17-66; MS 29794) (PROVISIONAL)
FLA 0363P	62/832,654		BANNISTER, C. WANG, BIALKOWSKA, V. YANG	SMALL MOLECULES FOR CANCER THERAPY THAT REDUCE THE EXPRESSION OF TRANSCRIPTION FACTORS KLF5 AND EGR-1 (DISCL. NO. 17-66; MS 29794) (PROVISIONAL)
FLA 0421P	20/027716	WO 20/210662	BANNISTER, C. WANG, BIALKOWSKA, V. YANG	SMALL MOLECULES FOR CANCER THERAPY THAT REDUCE THE EXPRESSION OF TRANSCRIPTION FACTORS KLF5 AND EGR-1 (PCT)
FLA 0488P	17/602,924		BANNISTER, C. WANG, BIALKOWSKA, V. YANG	SMALL MOLECULES FOR CANCER THERAPY THAT REDUCE THE EXPRESSION OF TRANSCRIPTION FACTORS KLF5 AND EGR-1 (U.S. NATIONAL PHASE) EFFICIENT RNA SWITCHES AND RELATED
EMM 0007P	62/915,258		FARZAN, ZHONG, H. WANG	EXPRESSION SYSTEMS (DISCL. NO. 19-05; MS 29809) (PROVISIONAL) EFFICIENT RNA SWITCHES AND RELATED
EMM 0027P	20/055495	WO 21/076563	FARZAN, ZHONG, H. WANG	EXPRESSION SYSTEMS (PCT) COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE AND METABOLIC
VIT 0002P	62/847,600		LASMÉZAS, ZHOU, BANNISTER	DISORDERS (DISCL. NO. 18-71) (PROVISIONAL) COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE AND METABOLIC
VIT 0003P	20/032903	WO 20/232255	LASMÉZAS, ZHOU, BANNISTER	DISORDERS (PCT)

VIT 0010P	17/610,758		LASMÉZAS, ZHOU, BANNISTER	COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE AND METABOLIC DISORDERS (U.S. NATIONAL PHASE) LASER-INDUCED CONFOCAL MICROSCOPE AND MICROFLUIDIC DEVICE FOR DIELECTROPHORETIC FLUORESCENCE- ACTIVATED DROPLET SORTING (DISCL. NO. 19- 14)
FLA 0365P	62/842,434		PAEGEL, CHAPUT, VALLEJO	LASER-INDUCED CONFOCAL MICROSCOPE AND MICROFLUIDIC DEVICE FOR DIELECTROPHORETIC FLUORESCENCE- ACTIVATED DROPLET SORTING (DISCL. NO. 19- 14)
FLA 0423P	20/031121	WO 20/223675	PAEGEL, CHAPUT, VALLEJO	LASER-INDUCED CONFOCAL MICROSCOPE AND MICROFLUIDIC DEVICE FOR DIELECTROPHORETIC FLUORESCENCE- ACTIVATED DROPLET SORTING (PCT)
FLA 0486P	17/607,008		PAEGEL, CHAPUT, VALLEJO	LASER-INDUCED CONFOCAL MICROSCOPE AND MICROFLUIDIC DEVICE FOR DIELECTROPHORETIC FLUORESCENCE- ACTIVATED DROPLET SORTING (U.S. NATIONAL PHASE) STRUCTRually DEFINED SIRNA-DUAL VARIABLE DOMAIN
TSR 2345P	62/864,755		KEL'IN, NANNA, RADER, THEILE, PIERSON, FITZGERALD	IMMUNOGLOBULIN CONJUGATES (DISCL. NO. 19-35; MS 29915) (PROVISIONAL) STRUCTRually DEFINED SIRNA-DUAL VARIABLE DOMAIN
TSR 2575P			KEL'IN, NANNA, RADER, THEILE, PIERSON, FITZGERALD, VOO	IMMUNOGLOBULIN CONJUGATES (AUSTRALIA) STRUCTRually DEFINED SIRNA-DUAL VARIABLE DOMAIN
TSR 2576P			KEL'IN, NANNA, RADER, THEILE, PIERSON, FITZGERALD, VOO	IMMUNOGLOBULIN CONJUGATES (CANADA) STRUCTRually DEFINED SIRNA-DUAL VARIABLE DOMAIN
TSR 2577P			KEL'IN, NANNA, RADER, THEILE, PIERSON, FITZGERALD, VOO	IMMUNOGLOBULIN CONJUGATES (EPO)

TSR 2578P			KEL'IN, NANNA, RADER, THEILE, PIERSON, FITZGERALD, VOO	STRUCTRUEALLY DEFINED SIRNA-DUAL VARIABLE DOMAIN IMMUNOGLOBULIN CONJUGATES (JAPAN) STRUCTRUEALLY DEFINED SIRNA-DUAL VARIABLE DOMAIN IMMUNOGLOBULIN CONJUGATES (DISCL. NO. 20-22) (PCT)
TSR 2427P	20/038475	WO 20/257483	KEL'IN, NANNA, RADER, THEILE, PIERSON, FITZGERALD, VOO	STRUCTRUEALLY DEFINED SIRNA-DUAL VARIABLE DOMAIN IMMUNOGLOBULIN CONJUGATES (U.S. NATIONAL PHASE) NOVEL SESQUITERPENOID ANALOGS (DISCL. NO. 19- 40; MS 29877) (PROVISIONAL)
TSR 2579P			KEL'IN, NANNA, RADER, THEILE, PIERSON, FITZGERALD, VOO	NOVEL SESQUITERPENOID ANALOGS (DISCL. NO. 19- 40) (PROVISIONAL)
FLA 0371P	62/714,785		DAI, DAVIS, ADIBEKIAN, HOCH, ZHANG	NOVEL SESQUITERPENOID ANALOGS (DISCL. NO. 19- 40) (PROVISIONAL)
FLA 0372P	62/746,126		DAI, DAVIS, ADIBEKIAN, HOCH, ZHANG	NOVEL SESQUITERPENOID ANALOGS
FLA 0424P	16/531,185		DAI, ADIBEKIAN, ZHANG, HOCH, DAVIS	NOVEL SESQUITERPENOID ANALOGS
FLA 0373P	19/045044	WO 20/033286	DAI, ADIBEKIAN, ZHANG, HOCH, DAVIS	NOVEL SESQUITERPENOID ANALOGS (PCT) INSULIN RECEPTOR- MEDIATED ENHANCEMENT OF GENE TRANSFER (DISCL. NO. 19- 36; MS 29994) (PROVISIONAL)
EMM 0008P	63/055,395		JACKSON, CHOE, FARZAN	INSULIN RECEPTOR- MEDIATED ENHANCEMENT OF GENE TRANSFER (PCT) COMPOUNDS AND MODULES FOR INHIBITION OF PRE-miR-21 AND THEIR USE IN TREATMENT OF CERTAIN CANCERS (DISCL. NO. 19- 46; MS 29885) (PROVISIONAL)
EMM 0028P	21/042200		JACKSON, CHOE, FARZAN	COMPOUNDS AND MODULES FOR INHIBITION OF PRE-miR-21 AND THEIR USE IN TREATMENT OF CERTAIN CANCERS (DISCL. NO. 19- 46; MS 29885) (PROVISIONAL)
FLA 0379P	62/927,247		DISNEY, CHILDS- DISNEY	COMPOUNDS AND MODULES FOR INHIBITION OF PRE-miR-21 AND THEIR USE IN
FLA 0453P	20/057914	WO 21/087084	DISNEY, CHILDS- DISNEY	

TREATMENT OF CERTAIN
CANCERS (PCT)

FLA 0380P	62/925,051		RADER, HWANG	NOVEL CONJUGATION CHEMISTRY FOR CATALYTIC ANTIBODY 38C2 (DISCL. NO. 19-27; MS 29892) (PROVISIONAL)
FLA 0456P	20/055768	WO 21/080846	RADER, HWANG	NOVEL CONJUGATION CHEMISTRY FOR CATALYTIC ANTIBODY 38C2 (PCT)
FLA 0381P	62/907,909		SIEGEL, BHOJ, RADER, GOYDEL	HUMANIZED ANTI-GDNF FAMILY ALPHA- RECEPTOR 4 (GRF-ALPHA- 4) ANTIBODIES AND CHIMERIC ANTIGEN RECEPTORS (DISCL. NO. 19-61) (PROVISIONAL)
FLA 0454P	17/037,203		SIEGEL, BHOJ, RADER, GOYDEL	HUMANIZED ANTI-GDNF FAMILY ALPHA- RECEPTOR 4 (GRF-ALPHA- 4) ANTIBODIES AND CHIMERIC ANTIGEN RECEPTORS (DISCL. NO. 19-61)
FLA 0455P	20/053303	WO 21/067290	SIEGEL, BHOJ, RADER, GOYDEL	HUMANIZED ANTI-GDNF FAMILY ALPHA- RECEPTOR 4 (GRF-ALPHA- 4) ANTIBODIES AND CHIMERIC ANTIGEN RECEPTORS (PCT)
FLA 0382P	62/943,005		DAVIS, VARKUTI, KEPIRO, MACMULLEN	MITOTHERAPEUTICS FOR THE TREATMENT OF BRAIN DISORDERS (DISCL. NO. 19-54; MS 29894) (PROVISIONAL)
FLA 0419P	62/977,931		DAVIS, LIU, VARKUTI, KEPIRO, MACMULLEN	MITOTHERAPEUTICS FOR THE TREATMENT OF BRAIN DISORDERS (DISCL. NO. 19-54, 20-03; MS 29894, 29939) (PROVISIONAL)
FLA 0451P	20/062052	WO 21/113127	DAVIS, LIU, VARKUTI, KEPIRO, MACMULLEN	MITOTHERAPEUTICS FOR THE TREATMENT OF BRAIN DISORDERS (PCT) (DISCL. NO. 19-54, 20-03, 20- 25)
FLA 0475P	21/070763		KAMENECKA, GREENMAN, SOLT	REV-ERB AGONISTS FOR TH17-MEDIATED INFLAMMATORY DISORDERS (PCT)
FLA 0398P	62/950,267		DISNEY, MOURADIAN	METHODS FOR INHIBITION OF ALPHA- SYNUCLEIN mRNA USING SMALL MOLECULES

				(DISCL. NO. 19-74; MS 29925)
FLA 0462P	20/065901	WO 21/127367	DISNEY, MOURADIAN	METHODS FOR INHIBITION OF ALPHA- SYNUCLEIN mRNA USING SMALL MOLECULES (PCT) TARGETED DEGRADATION OF THE ONCOGENIC MICRORNA 17-92 CLUSTER BY STRUCTURE-TARGETING LIGANDS (PCT)
FLA 0468P	21/023976	WO 21/202208	DISNEY	SCAFFOLDED ANTIGENS AND ENGINEERED SARS- COV-2 RECEPTOR- BINDING DOMAIN (RBD) POLYPEPTIDES (DISCL. NO. 20-28) (PROVISIONAL)
FLA 0427P	63/114,091		FARZAN, QUINLAN, MU, HE	SCAFFOLDED ANTIGENS AND ENGINEERED SARS- COV-2 RECEPTOR- BINDING DOMAIN (RBD) POLYPEPTIDES (DISCL. NO. 20-28) (PROVISIONAL)
FLA 0478P	63/232,024		FARZAN, QUINLAN, GUO, MU, HE, CHOE, ZHANG, BAILEY, ALPERT	TARGETED RNA DEGRADATION ALLOWS PRECISION REPURPOSING OF PROTEIN-TARGETED SMALL MOLEDDULE MEDICINES TO RNA (DISCL. NO. 20-27; MS 29995) (PROVISIONAL)
FLA 0432P	62/706,108		DISNEY	TARGETED RNA DEGRADATION ALLOWS PRECISION REPURPOSING OF PROTEIN-TARGETED SMALL MOLEDDULE MEDICINES TO RNA (PCT)
FLA 0479P	21/043937		DISNEY	SMALL MOLECULES THAT TARGET THE RNA THAT CAUSES ALS (DISCL. NO. 20-30) (PROVISIONAL)
FLA 0436P			DISNEY	CONVERSION OF A BIOLOGICALLY SILENT miRNA BINDING SMALL MOLECULE TO AN miRNA DEGRADER (DISCL. NO. 20- 48; MS 30020)
FLA 0440P	62/706,615		DISNEY	(PROVISIONAL) CONVERSION OF A BIOLOGICALLY SILENT miRNA BINDING SMALL MOLECULE TO AN miRNA DEGRADER (PCT)
FLA 0481P	21/047936		DISNEY, LIU	

FLA 0450P	63/094,117	DISNEY	METHOD FOR TREATING ALS/FTD THROUGH DEGRADATION OF RNA REPEAT EXPANSION (DISCL. NO. 20-42; MS 30010) (PROVISIONAL)
FLA 0484P	21/055408	DISNEY	METHOD FOR TREATING ALS/FTD THROUGH DEGRADATION OF RNA REPEAT EXPANSION (PCT)
FLA 0457P	63/084,594	DAI, CUI, CAI, ADIBEKIAN, DWYER	EFFICIENT TOTAL SYNTHESIS AND CHEMOPROTEOMICS CONNECT COMPLEX CURCUSONE
FLA 0483P		DAI, CUI, CAI, ADIBEKIAN, DWYER	DITERPENOIDS WITH ONCOGENIC PROTEIN BRAT1 (DISCL. NO. 20-58) (PROVISIONAL)
VIT 0005P	63/113,049	LASMEZAS, ZHOU	EFFICIENT TOTAL SYNTHESIS AND CHEMOPROTEOMICS CONNECT COMPLEX CURCUSONE
VIT 0006P	63/124,543	BANNISTER, LASMEZAS, ZHOU, KENNEDY	DITERPENOIDS WITH ONCOGENIC PROTEIN BRAT1 (PCT)
VIT 0007P	63/127,859	BANNISTER, LASMEZAS, ZHOU, ALBERTSON	NICOTINAMIDE DINUCLEOTIDE (NAD) DETECTION AND QUANTIFICATION (DISCL. NO. 20-61) (PROVISIONAL)
VIT 0008P	63/137,951	BANNISTER, LASMEZAS, ZHOU, ULLAH	COMPOUNDS AND USE THEREOF FOR TREATMENT OF NEURODEGENERATIVE, DEGENERATIVE AND METABOLIC DISORDERS (DISCL. NO. 20-68) (PROVISIONAL)

			(DISCL. NO. 20-68) (PROVISIONAL)
FLA 0464P	63/142,720	PAGE	TREATING DISORDERS ASSOCIATED WITH DYRK1A DYSFUNCTION (DISCL. NO. 21-03; MS 30065) (PROVISIONAL) COMPOUNDS AND USE THEREOF FOR TREATMENT OF NEURODEGENERATIVE, DEGENERATIVE AND METABOLIC DISORDERS (DISCL. NO. 20-68) (PROVISIONAL)
VIT 0009P	63/142,634	BANNISTER, LASMEZAS, ZHOU, RAHAIM	BROAD-SPECTRUM METASTASIS SUPPRESSING COMPOUNDS, AND THERAPEUTIC USES THEREOF IN HUMAN TUMORS (DISCL. NO. 21-14) (PROVISIONAL)
FLA 0469P	63/193,810	CANAANI, GOTTFRIED, DISNEY	QUINAZOLINE DERIVATIVES TARGETING r(CCUG) REPEATS IN MYOTONIC DYSTROPHY TYPE 2 (DISCL. NO. 21-01; MS 30090) (PROVISIONAL)
FLA 0474P	63/188,884	DISNEY	TARGETING RNAs ASSOCIATED WITH TAUOPATHIES WITH SMALL MOLECULES (DISCL. NO. 21-18) (PROVISIONAL)
ETI 0082P		DISNEY	FULLY HUMAN MONOCLONAL ANTIBODIES TARGETING SIGLEC-6 (DISCL. NO. 21-40) (PROVISIONAL)
TSR 2554P	63/278,725	RADER, CYR	DRUG-LIKE SMALL MOLECULES THAT TARGET THE mRNA ENCODING THE UNDRUGGABLE PROTEIN α -SYNUCLEIN (DISCL. NO. 21-19; MS 30137) (PROVISIONAL)
ETI 0084P		DISNEY	SMALL MOLECULE DEGRADATION METHOD FOR TREATING ALS/FTD (DISCL. NO. 21-48; MS 30140) (PROVISIONAL)
FLA 0489P	63/272,526	DISNEY	DNA-ENCODED LIBRARY-
FLA 0490P	63/287,814	DISNEY, PAEGEL	VERSUS-RNA-ENCODED

			LIBRARY SELECTION ENABLES DESIGN OF AN ONCOGENIC NON-CODING RNA INHIBITOR (DISCL. NO. 21-42; MS 30133) (PROVISIONAL) REV-ERB AGONISTS FOR TH17-MEDIATED INFLAMMATORY DISORDERS (DISCL. NO. 21-54) (PROVISIONAL) RNA-FOCUSED SMALL MOLECULE AND FRAGMENT LIBRARIES (DISCL. NO. 21-57) (PROVISIONAL) SMALL MOLECULE MODULATORS OF GPR139 COMPLEX (DISCL. 22-01) (PROVISIONAL) COMBINATORIAL ACTIVATION OF GABA(B) AND ALPHA-2 ADRENERGIC RECEPTORS FOR TREATMENT OF STRESS INDUCED DEPRESSION (DISCL. NO. 22-04) (PROVISIONAL) TARGETING PTCHD1 AND NEURONAL CHOLESTEROL AS A THERAPEUTIC STRATEGY TO ENHANCE SAFETY OF OPIOID ANALGESICS (DISCL. NO. 22-08; MS 30159) (PROVISIONAL) CONVERSION OF TWO BIOLOGICALLY SILENT mRNA BINDING SMALL MOLECULES TO mRNA DEGRADERS (DISCL. NO. 22-11; MS 30160) (PROVISIONAL) G ALPHA Q/11 INHIBITORS FOR USE AS AN ANALGESIC (DISCL. NO. 22-23; MS 30171) (PROVISIONAL) SMALL MOLECULE PROBES USEFUL AS BROAD SPECTRUM BACTERIAL INHIBITORS (DISCL. NO. 22-17) (PROVISIONAL)
FLA 0492P	63/291,771	KAMENECKA, SOLT, HE, LIZARZABURU, BOOKSER	
FLA 0493P		DISNEY MARTEMYANOV	
FLA 0495P	63/303,198	, STOVEKEN, SPICER, SCAMPAVIA	
FLA 0497P	63/320,588	MARTEMYANOV , SUTTON	
FLA 0498P	63/319,113	MARTEMYANOV , GRILL	
FLA 0500P		DISNEY	
FLA 0501P	63/324,879	MARTEMYANOV	
FLA 0502P		SPICER, SCAMPAVIA	